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AIM OF THIS THESIS
Immediately after the discovery of eotaxin it was suggested that this protein could
contribute to unravelling the mechanism of selective eosinophil migration during
allergic reactions. Since eosinophils are prominent cells in the pathology of allergic
airway inflammation, we hypothesised that eotaxin is an important mediator in
eosinophil-mediated disease. In this thesis we aimed to assess the role of eotaxin in
allergic asthma and viral respiratory infections, focussing on its role in development
of airway inflammation and airway hyperresponsiveness.
EOTAXIN
Eotaxin was first isolated from the broncho-alveolar lavage (BAL) fluid of guinea
pigs sensitised and challenged with ovalbumin. After purification of this protein, it
was demonstrated that eotaxin induced increased intracellular calcium
concentrations in eosinophils and eosinophil aggregation in vitro. Injection of this
chemotactic factor into the dermis of guinea pigs resulted in migration of radio-
labelled eosinophils to the site of injection (1). This first gave rise to the idea that
eotaxin induces selective eosinophil migration and might therefore be important in
eosinophil-associated diseases.
Due to its structure and its implication in eosinophil migration, eotaxin was
classified as a chemokine. Chemokines are a unique group of proteins involved in
migration of leukocytes to different parts in the body, both in non-inflamed and
inflamed conditions. These proteins are small inducible cytokines ranging from 8-10
kDa. More than 40 chemokines have been identified today. All chemokines share
common structures and have the ability to attract leukocytes. Chemokines are
classified into different sub-families based on the position of their first cystein
residues. The two largest and most studied groups of chemokines are CC- and CXC-
chemokines. In the later group, the first cystein residues are separated by another
amino acid. Eotaxin belongs to the CC-chemokine family. Nowadays, two other
groups are identified as C- and CXXXC-chemokines.
A new nomenclature for chemokines has recently been established. The chemokines
where numbered according to the order they were discovered (2). This means that
eotaxin is addressed as CCL11. In this thesis CCL11 will be referred as eotaxin.
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Human, mouse, rat and guinea pig eotaxin have been cloned so far (3-10). The
cDNA for human eotaxin encodes a 97 amino acid protein with a 23 amino-acid
leader sequence. The human gene of eotaxin is located on chromosome 17 (11).
Eotaxin displays some homology with other chemokines such as human monocyte
chemotactic protein-1 (MCP-1) (53%) and guinea pig MCP-1 (44%) (12).
Eotaxin receptor
Chemokines exert their action by binding to chemokine receptors on target cells,
which are classified according to their ligands, i.e. CC-chemokine receptors (CCR)
bind CC-chemokines and CXC-chemokine receptors (CXCR) bind only CXC-
chemokines (table 1). Chemokine receptors are G-protein-coupled receptors.
Activation leads to a cascade of cellular events of different intracellular signalling
pathways resulting in migration of cells toward high chemokine concentration.
Chemokines are redundant in their action on their target cells meaning all leukocytes
express more than one chemokine receptor (table 1). Furthermore, there is
promiscuity among the chemokines; most chemokines activate multiple chemokine
receptors and therefore are able to act on multiple leukocyte populations (13, 14).
The point of this redundancy is not known, but in this way the chemokine family
forms a stringently regulated network for leukocyte migration.
Although there is a lot of promiscuity among chemokines and their receptor, eotaxin
only binds to the CCR3 (10, 15). This point stresses the importance of the
involvement of eotaxin in migration of CCR3 expressing cells. Other chemokines
also bind to CCR3, but not exclusively. For example, besides binding to CCR3 the
chemokine RANTES can activate CCR1 as well, meaning that besides eosinophils
this chemokine also act on monocytes and dendritic cells.
Similar to other chemokine receptors, CCR3 is a seven trans-membrane G-protein
coupled receptor. Activation of CCR3 leads to a rise in intracellular Ca2+
concentrations resulting in eosinophil activation and migration Very little is known
about the signal transduction pathway (16). After binding of eotaxin the receptor is
internalised to down-regulate CCR3 from the surface of eosinophils (17).
Unlike the first believes that CCR3 is only expressed on eosinophils, it became clear
that also basophils, mast cells and Th2 cells express CCR3 on their surface (18-20).
Since all these cells are important in allergic asthma, might indicate that eotaxin and
its receptor are involved in the pathophysiology of this disease.
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Chemokine receptors
(CKR)
Ligands Cells
CC-CKR
CCR1 MCP-3, MIP-1α, RANTES Eosinophils, monocytes, activated
T-cells, dendritic cells
CCR2 MCP-1, -2, -3, -4 Basophils, monocytes, activated
T-cells, dendritic cells, NK-cells
CCR3 MCP-3, MCP-4 eotaxin-1,-2,-3
RANTES
Eosinophils, basophils, activated
T-cell
CCR4 TARC, MDC Activated T-cells, dendritic cells
CCR5 MIP-1α, MIP-1β, RANTES Monocytes, activated T-cells,
dendritic cells, NK-cells
CCR6 LARC Dendritic cells
CCR7 MIP-3β, SLC Activated T-cells
CCR8 I-309 Monocytes
CCR9 TECK Activated T-cells
CCR10 CTACK, MEC Activated T-cells, dendritic cells
CXC-CKR
CXCR1 IL-8, GCP-2 Neutrophils
CXCR2 IL-8, GCP-2, NAP-2, GRO-α, -β, -γ Neutrophils
CXCR3 IP-10, MiG, iTAC NK-cells, activated T-cells
CXCR4 SDF-1 Monocytes, T-cells
CXCR5 BLC T-cells, B-cells
CXXXC-CKR
CXXXCR1 Fraktalkine Monocytes, activated T-cells,
dendritic cells, NK-cells
C-CKR Lymphotactin Dendritic cells
Table 1: Chemokine receptors and binding chemokines expressed on various cells. Table
adapted from (21, 22).
Eotaxin generation
Under basal conditions eotaxin mRNA is expressed in a variety of tissues.
Moreover, constitutive eotaxin mRNA levels were found in the lungs, intestines,
spleen, liver, heart, thymus, testis, and kidney in guinea pigs, humans, and mice (4,
9). Finding of constitutive eotaxin mRNA expression suggests that eotaxin may play
a role in normal tissue homing and turnover of eosinophils (23).
Eotaxin-2 and -3
A few years after the discovery of eotaxin, eotaxin-2 was isolated, which was
quickly followed by the finding of eotaxin-3 (24, 25). The similarity between the
three forms of eotaxin is that these chemokines exclusively bind to CCR3 and not to
any other chemokine receptor. Structurally, eotaxin-2 and -3 share only 39 and 33 %
homology, respectively, with eotaxin. In contrast to eotaxin-1, their gene is mapped
on chromosome 7.
Chapter 1
12
Similar to eotaxin, binding of eotaxin-2 and -3 to CCR3 results in eosinophil
activation and migration. Though, eotaxin is a more potent signal compared to the
other forms of eotaxin. Comparable to eotaxin, expression of isoforms-2 and -3 is
increased after allergen challenge (26, 27). This thesis concentrates on eotaxin-1 and
is addressed to as eotaxin.
ASTHMA
Asthma is a multi-factorial complex disease of the airways characterised by
reversible airflow obstruction, bronchial hyperresponsiveness and chronic airway
inflammation (28). Both genetic and environmental factors are involved in the onset
of this disease. For instance, atopy is one of the most important genetic factors
linked to this illness (29). However, asthma prevalence is increasing rapidly, and
therefore can not only be explained by genetic factors. Environmental determinants,
such as house dust mite, occupational agents, cigarette smoke, and viral respiratory
infections are important in inducing this disease (30). In general, people predisposed
to atopy have excessive allergic reaction to common inhaled allergens. Many cells
and mediators are implicated in the pathology of asthma.
Allergic asthma
In allergic asthma upon an encounter with allergens, dendritic cells that line the
airways take up the antigen and, guided by a variety of chemokines, migrate to the
draining lymph nodes. Here, dendritic cells activate T and B cell. A subdivision of T
cells, Th2 cells are associated with allergic diseases. Activation of Th2 cells by
antigen presenting dendritic cells, leads to the production inflammatory cytokines
such as interleukin (IL)-4, IL-5, and IL-13, which are important inflammatory
cytokines in the cascade of events leading to allergy. Under the influence of IL-4
and IL-13 B-cells switch to production of immunoglobulin (Ig) E. IgE enters the
circulation and binds to high affinity receptors (FcεR1) for IgE, which are present
on mast cells and basophils. Antigen binding to IgE on mast cells results in mast cell
activation, inducing the early phase reaction characterised by constriction of airway
smooth muscle, vascular leakage, and mucus production. Four to six hours later, the
early phase reaction is followed by the late phase reaction. This phase is
characterised by excessive inflammation of the lungs resulting in airflow obstruction
induced by various cytokines derived from inflammatory cells. The majority of the
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recruited inflammatory cells consists of eosinophils and lymphocytes. This
inflammatory infiltrate induces mucus secretion, smooth muscle hypertrophy,
epithelial shedding, and thickening of the bronchial wall (28, 31, 32).
Viral respiratory infections
Besides allergens, other environmental agents can cause asthma, such as viral
respiratory infections. In otherwise healthy adults and children respiratory viruses,
e.g. rhinovirus, respiratory syncytical virus, and para-influenza virus, can cause
wheezing and other asthma-like symptoms. It was demonstrated that in 80-85% of
school-aged children with wheezing episodes tested positive for rhinovirus
demonstrating the importance of viruses (33).
In general, respiratory viruses infect epithelial cells of the airways, but do not cause
evident epithelial damage. Viruses induce and augment inflammatory reactions by
infecting and activating epithelial cells resulting in increased cytokine and
chemokine release (34, 35). Viral particles activate resident airway cells, such as
macrophages and granulocytes resulting in increased cytokine production and up-
regulation of adhesion molecules causing additional migration of inflammatory cells
(reviewed in (36)).
Eosinophils take part in the pathology of viral respiratory infections. Increased
numbers of eosinophils are present in lung tissue during viral infections. In addition
increased eosinophil specific mediators were detected in infected airways,
illustrating that eosinophils are activated. This increase in activated eosinophils
could be induced directly via stimulating eosinophils with virus, or indirectly by
activation of epithelial cells (37).
Experimental infection of human volunteers with rhinovirus resulted in airway
hyperresponsiveness, which coincided with increased levels of lymphocytes and
eosinophils (38). A correlation exists between lung function parameters and the
number and activation of eosinophils in sputum was demonstrated (39). Respiratory
viruses can directly attract and stimulate eosinophils, which might be the cause of
increased airway responsiveness. In a guinea pig model for virus-induced airway
inflammation, airway hyperresponsiveness and airway eosinophilia were associated
(40). Eosinophils present in the airway demonstrated piecemeal degranulation (41).
Furthermore, histamine was shown to be associated in the induction of airway
hyperresponsiveness (42). This illustrates that during viral infections in the airway
eosinophils and mast cells might play a prominent role in inducing airway
hyperresponsiveness.
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In asthmatic patients, viral respiratory infections are often the cause of exacerbations
(43). In the majority of patients with asthma exacerbations were correlated with
rhinovirus infections. In this process atopy is a major risk factor. Increased
histamine levels were measured in asthmatic patients infected with rhinovirus after
allergen challenge compared to non-asthmatic individuals. Hence, respiratory virus
infections can intensify both the early and late phase reaction in response to allergen
and is accompanied by increased mast cell mediator release, and recruitment of
eosinophils to the airways (37).
Thus, mast cells and eosinophils play a prominent role in both allergic asthma and
viral respiratory infections.
Mast cells
Mast cell progenitors are present in the bone marrow and in the circulation. Only
after these cells have reached the tissue they undergo final differentiation resulting
in the formation of different mast cell populations. This phenotype heterogeneity of
mast cells is reflected in different protease expression. In general, two mast cell
populations can be differentiated. First, mast cells that only express tryptase are
found in lungs and intestinal mucosa. Second, mast cells that express both tryptase
and chymase are found in skin, lymph nodes, and intestinal submucosa (44).
Mast cells have long been recognised as an important effector cell in initiating early
phase reactions. After a second encounter with the allergen, this protein can bind to
IgE labelled mast cells. Hereafter, cross-linking of the Fcε receptor by the
multivalent antigen results in mast cell activation. Exocytosis of pre-formed
mediators, e.g. histamine and serotonin, cause the early phase reaction (45). Besides
release of pre-stored mediators, mast cells also produce newly synthesised products
like eicosanoids and cytokines such as tumour necrosis factor-α (TNF-α), IL-3, IL-
4. (46). This indicates that mast cells might contribute to ongoing chronic
inflammation in asthma Furthermore, increased numbers of mast cells are present in
the airways during the late phase reaction.
Studies with mast cells deficient mice have contributed significantly to resolve the
role of mast cells in asthma. Some studies showed that airway hyperresponsiveness
and mast cells are associated. Although mast cells and their products can initiate
allergic reactions, it has been demonstrated that IgE independent processes can
induce these airway symptoms. Further, contribution of mast cells and its products
in airway eosinophilia are variable in different models.
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Eosinophils
Eosinophils are granulocytes, which arise from pluripotent cell in the bone marrow.
Under influence of cytokines, such as granulocyte-macrophage colony stimulating
factor (GM-CSF), IL-3 and eosinophil specific IL-5, precursor cells in the bone
marrow develop into mature eosinophils (47, 48). These mature cells are released
into the circulation. Under normal circumstances eosinophils leave the blood and
travel to the gut were they form the host’s main defence mechanism against
parasites. The life span of eosinophils is very short, but after appropriate stimulus
eosinophils produce GM-CSF, which makes them to survive in the tissue for more
then two weeks (49). Besides the important role of eosinophils in defence against
parasitic infections, these cells are involved in several recurrent disorders, for
instance allergic asthma (50).
Many studies have indicated that eosinophils are an important feature in the
pathology of asthma. Moreover, increased numbers of eosinophils are present in the
airways of asthmatic patients. In broncho-alveolar lavage (BAL) fluid, bronchial
biopsies and sputum increased numbers of eosinophils are present in mild, moderate
and severe asthmatics (51, 52). The percentages of eosinophils present in asthmatic
airways may rise up to 50% of the leukocytes.
To reach the airways, eosinophils have to undergo a multi-step process, which is
coordinated by various cytokines, adhesion molecules and chemokines. Initially,
eosinophils are released from the bone marrow and enter the circulation, resulting in
blood eosinophilia (48). This pool of eosinophils is responsive to stimuli that
augment their migration toward the tissue. The process of eosinophil maturation is
regulated by IL-5. The importance of this cytokine was demonstrated by genetic
manipulation of mice. Over-production of IL-5 induces a profound eosinophilia (47).
In contrast, deletion of the IL-5 gene caused a marked reduction of eosinophils in
the blood and airways after allergen challenge (53).
Ones the eosinophils are in the circulation; these cells are guided to the airways by
inflammatory mediators. Before they reach the airway lumen, eosinophils have to
pass the endothelium, cross the airway tissue, and the epithelium. Adhesion
molecules are involved in the whole process of transmigration. Pro-inflammatory
cytokines such as IL-1, IL-4 and TNF-α induce adhesion molecules on the
endothelium, thereby facilitating eosinophil translocation (54, 55). The first step in
initiating eosinophil translocation is rolling of eosinophils along the endothelial
cells. This process is mediated through a weak binding involving selectins. This is
followed by a more firm binding via integrins. VLA-4 (very late antigen-4) is
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present on eosinophils and binds to VCAM-1 (vascular cell adhesion molecule-1) or
LFA-1 (lymphocyte-function-associated antigen-1) and MAC-1 (complement
receptor-3) can bind to ICAM-1 (inducible cell adhesion molecule-1). This adhesion
is mediated by IL-3, IL-5 and GM-CSF. After this binding eosinophils move from
the apical site to the basolateral site of the endothelium, a process which requires
reversible adhesion. In this way, eosinophils enter the airways. To reach the airway
lumen eosinophils also have to pass the epithelial layer. Most of the previous
mentioned mediators are also involved in this process, with the exception of
VCAM-1 and selectins (reviewed (56)).
Figure 1: Proposed role of eotaxin in allergic asthma. (1) Mast cells become activated by
allergens and pro-inflammatory cytokines and are stimulated to produce cytokines such as
IL-4, IL-13, and TNF-α. (2) These cytokines are able to induce eotaxin production in
epithelial cells, smooth muscle cells, and fibroblasts. (3) In the meantime Th2 cells are
formed and produce IL-5. This cytokine is involved in the release of eosinophils from the
bone marrow, primes eosinophils and stimulates eosinophil survival. (4) Eosinophils enter
the circulation under influence of IL-5. Due to binding to adhesion molecules eosinophils
start rolling along the epithelium. Eventually the cell will transmigrate in the direction of
high eotaxin concentrations. (5) In the bronchial tissue eosinophils will survive for a long
time under the influence of autocrine IL-3 and GM-CSF, and IL-5. (6) In the next step
eosinophils reach the airway lumen. Here, activation of the eosinophils results in tissue
damage, which eventually can lead to airway hyper-responsiveness. (Figure adapted from
(62)).
Eosinophil
Blood
Endothelium
Epithelium
Bronchial tissue
Th2 cell
Mast cell
IL-3
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IL-5
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Chemokines can interact with the process of leukocyte extravasation at several
different steps. First of all, chemokines form a gradient across the tissue, which
guides the leukocyte to the direction of high chemokine concentration (57).
Secondly, chemokines interfere with binding of leukocytes to the epithelium by
influencing adhesion molecules. Chemokines increase the number of integrins on
leukocytes and enhances its adhesive activity (58-61). In this way, chemokines
facilitate leukocyte extravasation. Thirdly, once leukocytes are present at their
destination, chemokines activate these cells. Chemokines can activate the
respiratory burst resulting in production of oxygen intermediates, or may initiate
cytokine production (57).
Eotaxin interferes with the migration of eosinophils in similar ways (figure 1). First
of all, comparable to IL-5 eotaxin rapidly releases eosinophils from the bone
marrow, thus generating a pool of eosinophils in the circulation, which is available
for entering the tissue (63). Second, eotaxin forms a gradient in the tissue ensuing in
eosinophil migration to high eotaxin concentrations, both in vitro and in vivo (64-
66). Third, eotaxin modulates the affinity and expression of adhesion molecules
thereby facilitating eosinophil extravasation (60, 67). Fourth, eosinophils can be
activated by eotaxin, resulting in calcium mobilisation, actin rearrangement, release
of reactive oxygen species, and other eosinophil derived mediators such as IL-4 and
eosinophil-derived neurotoxin (EDN) (68-70).
Once eosinophils are present in the tissue they can become activated resulting in the
release of eosinophil specific basic proteins (71). Major basic protein (MBP),
eosinophil peroxides (EPO), eosinophil cationic protein (ECP), and EDN are toxic
mediators that are pre-stored in cytoplasmic granules. These proteins are released in
purpose of destroying parasitic invaders of the host. In contrast to these pre-stored
mediators, eosinophils are able to produce a wide variety of other newly synthesised
mediators. Eosinophils are a prominent source of eicosanoids, for example
leukotriene C4 (LTC4). In addition, these cells produce cytokines such as GM-CSF
and IL-4 (figure 2).
Eosinophils become activated after stimulation by various products, for example
through Fc receptors present on the membrane. Engagement of the Fcε, Fcα or Fcγ
(receptors for immunoglobulin (Ig) E, IgA and IgG, respectively) triggers release of
eosinophil granules (73). In most tissues eosinophils undergo piecemeal
degranulation (74). After allergen challenge eosinophil cytolysis is a method of
eosinophil degranulation (75).
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There is a correlation between airway symptoms, such as airway
hyperresponsiveness, and the number of eosinophils in the airway (76). A
correlation was shown between the number of eosinophils present in the lungs and
the magnitude of the early phase reaction and late phase reaction (77, 78). In asthma
patients the number of eosinophils in the airways correlated with lung function
parameters and products of activated eosinophils such as cationic proteins are able
to directly induce airway hyperresponsiveness (79, 80). In addition, eosinophils can
cause airway hyperresponsiveness in indirect ways, for instance by damaging
airway epithelium and interactions with sensory nerves (81, 82). Frequently,
eosinophils in bronchial biopsies have a partial degranulated appearance and
eosinophil-derived mediators are often detectable in BAL fluid and sputum of
asthma patients (51, 83). This indicates that eosinophils in the airways of allergic
asthmatics are activated, and might play a role in decreased airway function.
Figure 2: Several eosinophil products implicated in establishing allergic response. (Figure
adapted from Pearlman (72)).
Despite clear evidence that eosinophils and their toxic products can induce airway
hyperresponsiveness, the role of eosinophils in the pathogenesis of asthma is
currently under consideration. Numerous clinical and animal studies have shown
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that airway hyperresponsiveness can exist without the presence of airway
eosinophils (84-86). This may support the idea that airway hyperresponsiveness and
airway eosinophilia are independently regulated but closely interrelated.
Eotaxin and inflammation
The importance of eotaxin in allergic asthma still needs to be elucidated. Increased
eotaxin protein levels were measured in the BAL fluid of atopic asthmatic people
compared to healthy controls. Furthermore, increased levels of eotaxin mRNA and
protein were detectable in epithelium and submucosa of asthmatic patients (87).
Additionally, the levels of eotaxin correlated with the number of eosinophils in the
lung (88). Allergen inhalation resulted in elevated levels of eotaxin and this increase
correlated well with eosinophil migration into sputum (89). Moreover, CCR3 mRNA
is increasingly expressed in asthmatic humans compared to non-asthmatic controls
(90). Interestingly, eotaxin levels in plasma are also elevated in asthmatics and
correlate with the severity of the disease (91, 92).
The major cell source of eotaxin are epithelial and endothelial cells, but also smooth
muscle cells, mast cells, fibroblast and eosinophils can produce eotaxin (93-96). Up-
regulation of eotaxin is dependent on the transcription factors nuclear factor-κB and
STAT-6 (signal transducer and activator of transcription-6) (97). Allergen challenge
results in the formation of pro-inflammatory cytokines, like TNF-α, IL-1β, IL-4, IL-
13 or bradykinin, which in their turn stimulate epithelial and endothelial cells to
produce eotaxin (figure 1, ref (98, 99). Viral respiratory infection can directly
activate epithelial cells to produce eotaxin (34).
Actions of eotaxin in animal models
As a tool to study the mechanisms behind the pathological features of asthma,
animal models are regularly used. Usually, mice or guinea pigs are sensitised with
allergen such as ovalbumin, aspergillus, or house dust mite, with or without the
presence of an adjuvant. After sensitisation the animals are challenged in the
airways once or repeatedly with allergen. This treatment gives rise to several
measurable parameters characteristic of allergic asthma, such as formation of
antigen specific IgE, airway hyperresponsiveness, cellular infiltration in BAL fluid,
histological changes, and alterations in cytokine levels.
A great number of studies were undertaken to study the relationship between
eosinophil migration and eotaxin in animal models for allergic inflammation. A
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consistent feature of animal models for allergic asthma is airway eosinophilia.
Interestingly, this increase in eosinophils in the airways correlates well with the
expression of eotaxin mRNA. As quick as three hours after allergen challenge
eotaxin gene expression is increased with 25-fold in the lungs of guinea pigs (100).
Often, eosinophil influx into the airways is proceeded by increased levels of eotaxin
protein (101, 102). This indicates that eotaxin might be involved in eosinophil
migration to the airways in response to allergen challenge.
To show the importance of eotaxin in allergen induced airway symptoms; many
investigators tried to block the allergic response using eotaxin-neutralising
antibodies. Treatment of sensitised mice with neutralising antibodies during allergen
challenge period resulted in decreased eosinophil migration to the airways in
response to the allergen (103). This reduction in airway eosinophilia contributed to a
reduction of airway hyperresponsiveness (104). Another tool to investigate the role
of eotaxin in allergic inflammation is offered by the construction eotaxin knockout
mice. Two studies have investigated eosinophil trafficking in these mice, resulting
in conflicting evidence. One study showed a reduction in eosinophil migration in
response to allergen challenge (105), while in the other study airway eosinophilia
existed without the presence of eotaxin (106).
Eotaxin and IL-5
In both guinea pigs and mice eotaxin-induced eosinophil migration is greatly
enhanced by pre-treatment of mice with IL-5 (107, 108). It is generally believed that
during an inflammatory response both eotaxin and IL-5 are produced. IL-5 promotes
eotaxin responsiveness and prolongs eosinophil survival, thereby enhancing the
eotaxin-induced eosinophil migration.
In an elegant study, it was shown that in eotaxin/IL-5 knockout mice no peripheral
blood eosinophilia or tissue eosinophilia could be induced by allergen challenge
(109). In contrast, in IL-5 knockout mice and in eotaxin knockout mice the
eosinophilia induced by antigen was reduced but still present. Thus, eotaxin and IL-
5 co-operate to selectively regulate tissue eosinophilia.
Effects of eotaxin on Th2 cells, basophils and mast cells
Basophils accumulate in allergic sites, and are an important source of inflammatory
mediators. In vitro, basophils migrate towards high eotaxin concentrations. Eotaxin
elicited a slight release of histamine and leukotrienes by in IL-3 primed basophils
(110). Mast cell migration is induced by CCR3 agonists (111). Although, eotaxin
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induced an influx of intracellular calcium, mast cell degranulation has not been
demonstrated (19, 112). Additionally, eotaxin is involved in growth and
differentiation of mast cell progenitor (113).
T-cells express a wide variety of chemokines on their surface (114). Some of these
chemokines are markers for a subset of T-cells; for instance CCR3 is exclusively
expressed on Th2 cells (20). Eotaxin is able to induce cell migration and activation
of Th2 cells (114). In contrast, some studies had difficulties in demonstrating
expression of this receptor on T-cells (19).
OUTLINE OF THIS THESIS
In brief, since eotaxin is involved in migration and activation of eosinophils,
basophils, Th2 cells, and mast cells, which all play a prominent role in allergic
reactions and viral respiratory infections, we hypothesis that eotaxin is implicated in
the development of asthma. Data presented in this thesis focus on the role of eotaxin
in airway eosinophilia and airway hyperresponsiveness, in mice, guinea pigs and
humans.
Basically the investigations addressed three questions:
1. Does eotaxin instillation in the airways induce airway eosinophilia and
airway hyperresponsiveness?
This was done in naïve mice (chapter 2) and human volunteers (chapter 6). In the
first chapter, we aimed to assess whether eotaxin directly induced airway
hyperresponsiveness in mice. Tracheas of mice were incubated with eotaxin and
direct contraction of airway smooth muscle and the tracheal reactivity to muscarin
receptor agonists was determined. Furthermore, it was investigated whether eotaxin
installation in the airways, either alone or in combination with IL-5, induced
eosinophil trafficking to the airways and airway hyperresponsiveness (chapter 2). In
chapter six, the results of a randomised placebo-controlled crossover study, in which
mild asthmatic volunteers inhaled eotaxin, is discussed. After inhalation of eotaxin,
the percentage of sputum eosinophils, exhaled nitric oxide, and lung function was
determined.
2. Is antigen- or virus-induced airway inflammation and airway hyper-
responsiveness regulated by eotaxin?
As a tool to investigate this we used a mouse model for allergic asthma (chapter 3)
and a guinea pig model for viral respiratory infections (chapter 4) In these models
Chapter 1
22
we attempted to block the airway response to these agents by blocking eotaxin or its
receptor. In chapter 3, mice sensitised and challenged with ovalbumin showed a
considerable degree of airway eosinophilia and airway hyperresponsiveness (115). In
airways of these mice we measured eotaxin concentrations. Further, we tried to
increase asthma symptoms by instilling additional eotaxin in the airways of
ovalbumin treated mice. Moreover, consequences of treating ovalbumin-sensitised
mice with anti-eotaxin antibodies during the challenge period were investigated.
Likewise, viral respiratory infections can cause airway eosinophilia and airway
hyperresponsiveness (116). In chapter 4 we assessed the role of eotaxin in a guinea
pig model for viral respiratory infections.
3. Can eotaxin activate mast cells and thereby induce airway inflammation or
hyperresponsiveness?
Since mast cells express CCR3 as well, we examined the effect of eotaxin on murine
bone marrow-derived mast cells (117). It was investigated whether these cells
express CCR3 and whether stimulation of the CCR3 receptor resulted in mast cell
activation (chapter 5).
The final conclusions are summarised in chapter 7.
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SUMMARY
Airway eosinophilia and airway hyperresponsiveness are two characteristic features
of asthma. Eotaxin is a chemokine involved in trafficking of eosinophils to the site
of inflammation. In this study we aimed to assess whether eotaxin can induce airway
hyperresponsiveness in mice. The direct effect of eotaxin and the tracheal reactivity
to methacholine after pre-incubation with eotaxin was measured in naïve mice.
Moreover, airway inflammation and airway responsiveness in vivo was assessed in
mice treated intratracheally with eotaxin with or without an extra dose of
intravenous administered interleukin-5. Eotaxin had no direct effect on mouse
tracheas in vitro, and the airway reactivity to methacholine was not modulated by
eotaxin pre-incubation. Furthermore, intratracheal treatment of mice with eotaxin
did not effect the number of eosinophils and airway responsiveness in vivo. Similar
results were found in the presence of an additional dose of interleukin-5. In
conclusion, eotaxin alone does not induce airway hyperresponsiveness or eosinophil
migration to the airways, with or without the presence of interleukin-5 in naïve
mice.
INTRODUCTION
Airway hyperresponsiveness is a prominent feature of asthma, characterised by
increased responsiveness of airway smooth muscle to non-specific stimuli. In the
majority of asthmatic patients airway hyperreactivity coincides with an influx of
inflammatory cells to the airways. The infiltrate predominantly consists of
eosinophils. An increased number of these cells are found in the airway wall,
broncho-alveolar lavage (BAL) fluid, and sputum of asthmatic patients (1, 2). The
number of eosinophils in the airways correlates well with the severity of asthma (3,
4). Activated eosinophils in the airways release toxic proteins. These toxic
mediators can induce airway hyperactivity directly or cause epithelial damage
resulting in airway hyperresponsiveness (5). In this way, eosinophils could be
important in the pathophysiology of asthma.
Eotaxin is one of the most potent chemokines involved in eosinophil migration. This
chemokine was first isolated from the BAL fluid of guinea pigs sensitised and
challenged with ovalbumin (6). This protein is able to induce eosinophil migration,
in vitro and in vivo (6, 7). Besides its chemotactic activity, eotaxin can activate
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eosinophils, resulting in an increase of intracellular calcium concentrations (8, 9).
Eotaxin-induced eosinophil migration is enhanced in presence of interleukin (IL)-5
(10). During inflammation increased levels of eotaxin are detectable in BAL fluid of
asthmatic patients (11-13). This increase in eotaxin concentration coincides with
trafficking of eosinophils to the airway (14). In a mouse model for allergic asthma,
treatment with anti-eotaxin antibodies resulted in a decrease in eosinophil migration
to the airways and reduced airway hyperresponsiveness compared to control-treated
mice (15). This suggests that, besides involvement of eotaxin in eosinophil
trafficking, eotaxin might be involved in induction of airway hyperresponsiveness as
well.
The aim of the present study was to examine whether eotaxin is able to induce
airway hyperreactivity. The direct effect of eotaxin on a mouse trachea was studied.
Airway responsiveness was determined in vitro after eotaxin incubation or in vivo
after intratracheal administration of eotaxin in mice. In these mice, the numbers of
eosinophils in the airways and peripheral blood were enumerated, and airway
responsiveness was measured. The experiments were also performed in combination
with an intravenous injection of IL-5.
MATERIALS AND METHODS
Animals
In these experiments male specified pathogen free BALB/c mice of 6-8 weeks of
age were obtained from the Central Animal Laboratory at Utrecht University, The
Netherlands. They were housed under controlled condition in macrolon cages
containing 12 mice per cage. Water and standard chow was presented ad libitum.
Dutch committee of animal experiments approved the experiments described in this
paper.
Isometric measurements of tracheal reactivity
Tracheal reactivity was measured as previously described (16). In short, mice were
killed by an overdose of sodium pentobarbital (Nembutal, 0.2 ml, 60 mg/ml). The
tracheas were carefully dissected and cleared from connective tissue under a
binocular microscope. One piece of nine cartilage rings of the trachea, from just
below the larynx, was placed in an organ bath coupled to an isometric transducer.
The organ bath contained 10 ml Krebs’ solution (118 mM NaCl, 4.7 mM KCl, 2.5
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mM CaCl.6H2O, 0.5 mM MgCl2.6H2O, 25.0 mM HaHCO3, 1.0 mM NaHPO4.H2O,
11.1 mM glucose), was aired with carbogen (95% O2 and 5% CO2) and kept at a
constant temperature of 37°C. The pre-tension of the trachea was kept on 1,000 mg.
The tracheas were allowed to stabilise for one hour before tracheal reactivity was
measured. Tracheal reactivity was assessed by measuring the contraction to eotaxin
(10-9–10-12M) or to methacholine (10-9–10-3M). Isometric measurements were
expressed as changes in mg force. In stated experiments tracheas were incubated
with eotaxin (10-8 M, dissolved in Krebs’ solution) for half an hour prior to
placement in the organ bath.
Treatment of mice with eotaxin and IL-5 in vivo
Treatment with IL-5: Two treatment protocols were used. One group of mice
received one injection of IL-5 (4 µg/mouse), intravenously, blood samples were
taken on different time-points (0, 15, 30, 60 or 120 minutes) after the injection.
Another group of mice was treated on three consecutive days with IL-5
intravenously (1 or 10 µg/mouse/day). Blood was retrieved for analysis 24 hours
after the last IL-5 injection. Control treated animals were injected with saline.
Treatment with eotaxin: Mice were anaesthetised with a short lasting inhalation
anaesthetic (Halothane). Eotaxin (50 µl, 10 µg/ml saline 0.1% BSA, Peprotech,
Heerhugowaard, The Netherlands) was applied intratracheally. Control animals
were treated in the same manner with saline 0.1% BSA. In stated experiments, this
was done 18 hours after IL-5 injection. Several time-points (three or 18 hours) after
eotaxin mice were sacrificed
Airway responsiveness in vivo
Airway responsiveness was measured in mice using whole body plethysmography
(Buxco, Sharon, CT, USA). Unrestrained, unanaesthetised mice were placed in a
whole-body chamber. Airway responsiveness was measured by aerosolising
increasing concentrations of metacholine (1.6 mg/ml saline to 50 mg/ml saline) for
three minutes in the chamber. Airway responsiveness was expressed as enhanced
pause (Penh) (17).
Blood cell differentiation
Blood was retrieved by heart punction and 40 µl was dissolved in 20 µl heparin
(1000 U/ml). This was used for enumerating the number of leukocytes. One drop of
Chapter 2
36
blood was smeared on a slide and stained with Diff Quick (Merz & Dale, Dudingen,
Switzerland) for differential cell counts.
Broncho-alveolar lavage
A canula was inserted in the trachea. The lungs were lavaged 4 times with 1 ml
phosphate buffered saline (PBS, 37°C). The fractions were stored on ice. Thereafter,
the samples were centrifuged for 10 minutes, 300 g. Supernatant of the first fraction
was stored at -70°C for further analysis. The cells of all four fractions were pooled
and resuspended in 100 µl PBS. These cells were enumerated and cytospins were
prepared. These cytospins were stained with Diff Quick (Merz & Dale, Dudingen,
Switzerland) for differential cell counts.
Data analysis and statistics
Data are represented as mean ± SEM (standard error of the mean). Differences in
dose-response curves were analysed with repeated measures ANOVA (analysis of
variance) followed by a LSD post-hoc test for multiple comparison. Differences in
data on cell number after eotaxin were analysed with Student’s t-test. Other data
were analysed with a one-way ANOVA followed by a LSD post-hoc test.
Correlation was demonstrated by way of linear regression. Data were considered as
statically different if p < 0.05.
Figure 1: Tracheal reactivity to metacholine (10-8-10-9 M) 30 minutes after incubation with
10-8 M eotaxin (open circles), or control solution (con, closed circles) in an organ bath set-
up. Results are expressed as mean ± SEM.
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RESULTS
Direct effect of eotaxin
To investigate the effect of eotaxin on mouse trachea, increasing concentrations of
eotaxin (10-12 - 10-9 M) were added to the mouse trachea in an organ bath set-up.
Eotaxin by itself did not induce contraction of the tracheal smooth muscle.
To examine whether eotaxin was able to influence airway responsiveness, mouse
tracheas were incubated with eotaxin (10-8 M) for 30 minutes in a 96-wells plate. In
an organ bath set-up eotaxin incubation did not alter the responsiveness of mouse
tracheas to methacholine (figure 1).
In vivo effects of eotaxin
Intratracheal injection of eotaxin did not result in changes in the number of
eosinophils in the BAL fluid three hours after injection (figure 2a). Furthermore, this
treatment did not alter airway responsiveness to methacholine (figure 2b). Similar
results were obtained with 18 hours after treatment with eotaxin.
IL-5 a Blood eosinophils b
0 1.19 ± 0.232
1.0 0.86 ± 0.41
10 0.90 ± 0.41
Co-operation with interleukin-5
In order to increase the number and responsiveness of eosinophils, mice were
treated with 4 µg IL-5/mouse intravenously. This treatment did not result in
increased blood eosinophils at 15, 30, 60 or 120 minutes after injection (data not
shown). Therefore, another set of mice was treated for a longer period of time.
These mice received three injections of IL-5 (1 or 10 µg/mouse/day) intravenously.
This treatment did not result in blood eosinophilia either (table 1).
Despite the fact that IL-5 was not able to induce blood eosinophilia, it might be that
IL-5 primed the circulating eosinophils. Therefore, mice were treated with PBS or
IL-5 (10 µg/mouse, intravenously) 18 hours prior to saline or eotaxin (500
ng/mouse, intratracheally) administration. Three hours after eotaxin treatment
airway responsiveness, number of eosinophils in blood and BAL, were assessed.
Treatment with IL-5 did not result in significantly increased numbers of eosinophils
(table 2).
Table 1: Number of eosinophils in blood (bx104)
of mice treated three days IL-5 (a 0, 1, or 10
µg/mouse/day). No increase in blood
eosinophils was demonstrated. Results are
expressed as mean ± SEM.
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Figure 2: A Differential cell counts and total number of broncho-alveolar lavage cells in
mice 3 hours after intratracheal injection with eotaxin (grey bars) or saline (black bars).
BAL cells are differentiated into eosinophils, neutrophils, mononuclear cells (MNC).
Eotaxin did not change cell numbers. B Airway responsiveness (Penh) to methacholine in
vivo 3 hours after intratracheal injection with eotaxin (grey bars) or saline (black bars).
Eotaxin treatment did not alter airway responsiveness. Similar results were obtained after
18 hours (data not shown). Results are expressed as mean ± SEM.
Treatment Blood eosinophils a BAL eosinophil b Emax c
PBS-sal 1.15 ± 1.26 0.5 ± 0.1 4.78 ± 0.42
PBS-eotaxin 3.95 ±2.31 0.0 ± 0 5.44 ± 0.59
IL-5-sal 3.85 ± 1.25 0.0 ± 0 4.51 ± 0.24
IL-5-eotaxin 4.15 ± 1.15 0.0 ± 0 6.04 ± 1.1
Table 2: Mice treated with IL-5 or PBS (intravenously) received an intratrachal injection
with eotaxin or saline (sal) 18 hours later. Three hours after eotaxin treatment airway
responsiveness to methacholine (in vivo), number of eosinophils in blood and BAL, and
eosinophil peroxidase levels in lung homogenates were assessed. a Number of eosinophils
in blood (x104). b Percentage of eosinophils in the BAL fluid of total number of
leukocytes. c Maximal response to the highest dose of methacholine (Penh). Data are
expressed as mean ± SEM.
DISCUSSION
The action of eotaxin is restricted to eosinophils, basophils, Th2 cells, and mast cells
(18-21). The present study focussed on airway eosinophilia and airway
hyperresponsiveness. No effect of eotaxin was demonstrated both in vitro and in
vivo. Eotaxin did not effect tracheal reactivity in vitro, nor did it induce eosinophil
migration or alter airway responsiveness in vivo, even in combination with IL-5.
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The fact that eotaxin application into the airways did not result in eosinophil
migration is conflicting with recent published data. It is often shown that eotaxin is
involved in eosinophil migration. Application of eotaxin into the skin and airways
resulted in eosinophil migration from the blood to the skin or airways, respectively
(22, 23). There are some explanations why eotaxin did not induce eosinophil
migration in our experimental set-up. First, in other papers guinea pigs or IL-5
transgenic mice were used to show eosinophil migration in response to eotaxin.
After intranasal administration of eotaxin an eosinophil influx was detected in IL-5
transgenic mice while in their normal littermates only a small increase was detected
(23). Both guinea pigs and IL-5 transgenic mice have more circulating eosinophils
compared to BALB/c mice used in this study. Therefore, it was decided to treat
animals with IL-5 in order to increase the number of eosinophils in the circulation.
Furthermore, IL-5 primes eosinophils to respond to eotaxin (10). Surprisingly,
treatment with IL-5 did not alter the response to eotaxin administration. It might be
that the concentrations of IL-5 were too low or a more sustained basal expression is
necessary.
Second, the eotaxin concentration used for these experiments is known to induce
eosinophil migration in guinea pigs and IL-5 transgenic mice. Maybe, in the
experiments discussed here, higher concentrations of eotaxin are necessary, since
there are fewer circulating eosinophils. It is certain that eotaxin reaches the airways
using intratracheal administration. However, maybe eotaxin is broken down very
fast by proteases and is therefore not able to exert its action.
A third explanation why eotaxin did not induce eosinophil migration might be that
eotaxin is not able to induce eosinophil migration by its self. During an
inflammatory reaction, like asthma, lots of mediators are produced. Eosinophil
exudation is co-ordinated by many mediators. For example, adhesion molecules
need to be activated or upregulated so they can interact with eosinophils which role
along the endothelium, and eventually extravagate (24, 25). Other mediators co-
operate with eotaxin, which results in homing of eosinophils.
Our findings indicate that eotaxin does not directly influence airway responsiveness.
The involvement of eotaxin in airway hyperresponsiveness is probably indirect by
attracting and activating eosinophils. The fact that we could not induce eosinophil
migration to the airways might explain why these mice do not display airway
hyperresponsiveness. Gonzalo and colleagues showed that blocking eotaxin in a
murine model for allergic inflammation resulted in decreased airway responsiveness
compared to mice treated with control antibody (15). However, this effect could be
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indirect since in these mice also the number of eosinophils in BAL is decreased,
meaning that in this model eosinophils are involved in the induction of airway
hyperresponsiveness, rather then eotaxin itself.
Activated eosinophils are able to release toxic products, which can cause epithelial
damage, eventually leading to airway responsiveness (26). The mere presence of
eosinophils in the airways of mice does not necessarily mean that airway
hyperresponsiveness is initiated. Only activated eosinophils could be involved in
increased responsiveness of the lungs. In a model for eotaxin and IL-5 over-
expression in the airways of mice, it was shown that eotaxin and IL-5 induced
airway eosinophilia, but not airway hyperresponsiveness. In those experiments,
antigen inhalation in combination with IL-5 and eotaxin was required for eosinophil
degranulation and airway hyperresponsiveness to occur (27). Apparently, other
factors potentate the effect of eotaxin during an allergic reaction.
Since eosinophils play an important role in the pathophysiology of asthma, it is
important to investigate the events leading to tissue eosinophilia. One of the striking
things is that the influx of inflammatory cells predominantly consists of eosinophils.
This suggests that specific chemo-attractants, like eotaxin are indeed involved.
Whether or not the eosinophil is involved in the induction of airway responsiveness,
it is still worthwhile to investigate the events leading to airway eosinophilia and its
importance in asthma.
Eotaxin in naïve mice
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SUMMARY
Eotaxin is a chemokine involved in eosinophil migration. Eosinophils are a
prominent feature in allergic airways. In this paper, we investigated the role of
eotaxin in a mouse model for allergic asthma. The response to ovalbumin aerosols in
ovalbumin sensitized mice was modulated by either treatment with eotaxin
antibodies or additional eotaxin, to suppress or promote the development of both
airway hyperresponsiveness or airway inflammation. Further, eotaxin levels were
measured in lung and broncho-alveolar lavage fluid after challenge of mice with
ovalbumin or saline. Finally, the numbers of eosinophils in the BAL fluid and
airway hyperresponsiveness were related to eotaxin concentrations. Repeated
ovalbumin challenges in sensitized mice resulted in airway hyperresponsiveness and
increased numbers of eosinophils in the broncho-alveolar lavage fluid compared to
saline challenged animals. Administration of eotaxin antibodies during the challenge
period did not prevent development of these asthma-like symptoms. Furthermore,
administration of additional eotaxin after the last challenge did not result in
increased airway responsiveness or airway eosinophilia in saline or ovalbumine
challenged animals. In contrast, eotaxin concentrations were markedly increased in
lungs and broncho-alveolar lavage fluid of ovalbumin challenged mice. Although
increased levels of eotaxin were detected, there was no correlation with the number
of eosinophils in lavage fluid or airway hyperresponsiveness. From these
experiments it was concluded that although eotaxin is up-regulated in a murine
model for allergic airway inflammation, this chemokine is not involved in the
development of airway eosinophilia or airway hyperresponsiveness in this mouse
model for allergic asthma.
INTRODUCTION
Airway inflammation is a key feature of allergic asthma (1). The late asthmatic
phase reaction to an allergen often coincides with an increase of inflammatory cells
in the airways. This influx of cells predominantly consists of eosinophils. In
asthmatic patients increased numbers of these cells are detectable in the submucosa
of bronchial biopsies, and in broncho-alveolar lavage (BAL) fluid (2). Whether the
number of eosinophils is associated with disease severity is currently under debate.
Although some studies showed that there is a relationship between the number of
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eosinophils in the airways and the degree of airway hyperresponsiveness (another
key feature of asthma), this association is weak and might indicate that these
phenomena might not be dependent on each other (3, 4). Nevertheless, an influx of
eosinophils into the airways is unmistakably associated with allergic asthma.
The mechanism underlying eosinophil migration to the airways remains intriguing.
Chemokines are small inducible cytokines involved in trafficking and activation of
leukocytes. Since different types of inflammatory cells express particular chemokine
receptor, chemokine binding to a receptor provides a specific signal for restricted
cell migration (5). Eotaxin is a chemokine, which binds to the CC-chemokine
receptor (CCR3) (6). This receptor is present on eosinophils, Th2 cells, basophils
and mast cells (7-9). As all these cells are important in asthma, it is believed that
eotaxin is involved in the pathogenesis of this disease. Indeed, eotaxin and CCR3
mRNA and protein are up regulated in airways and blood of asthmatic patients (10-
13). Eotaxin induces eosinophil migration in the direction of high eotaxin
concentrations, both in vitro and in vivo (14). Animal models indicated that eotaxin
injection resulted in trafficking of these leukocytes to the site of injection (15).
Interleukin-5 enhances the responsiveness of eosinophils to eotaxin (16).
The objective of the present study was to assess whether eotaxin is implicated in
allergen induced airway inflammation and airway hyperresponsiveness. As a tool to
investigate the development of these two phenomena, a murine model for allergic
asthma was used. Mice were sensitized and challenged with ovalbumine, which lead
to formation of asthma like-symptoms, e.g. increased levels of IgE, airway
hyperreactivity to methacholine and serotonin, and influx of eosinophils to the
airway lumen (17). The first question to address was whether blocking of eotaxin
with anti-eotaxin antibodies prevented airway hyperresponsiveness and
inflammation. Second, does eotaxin administration worsen asthma features? Third,
is eotaxin expressed in the airways of mice challenged and sensitized with
ovalbumin?
MATERIALS AND METHODS
Animals
In these experiments male specified pathogen free BALB/c mice of 6-8 weeks of
age were obtained from the Central Animal Laboratory at Utrecht University, The
Netherlands. They were housed under controlled condition in macrolon cages
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containing 12 mice per cage. Water and standard chow was presented ad libitum.
Dutch committee of animal experiments approved the experiments described in this
paper.
Treatment
At 6-8 weeks of age mice received intraperitoneal injection of 10 µg ovalbumin
(grade V, Sigma, Zwijndrecht, The Netherlands) in 0.5 ml saline every other day, 7
times. Four weeks after the last sensitization, mice were challenged with ovalbumin
aerosols (2 mg/ml, 5 min) on 8 consecutive days. Vehicle treated animals were
challenged with saline. Twenty-four hours after the last challenge, airway reactivity
was measured, and blood and BAL were analyzed.
In stated experiments mice were treated with neutralizing anti-eotaxin antibodies
(R&D, Abingdon, UK) during the challenge period 30 minutes before the challenge
on day 0, 3, and 7 or days 5, 6, 7. The antibodies were injected intravenously
(20µg/mouse/ time). Rat IgG (rIgG) was used for control antibody treatment.
In some experiments additional eotaxin (500 ng/mouse, R&D, Abingdon, UK) was
injected intravenously 24 hours after the last ovalbumin challenge. Thirty minutes, 5
hours and 24 hours after eotaxin injection airway responsiveness was measured.
Twenty-four hours after eotaxin treatment blood and BAL were taken.
Airway responsiveness in vivo
Airway responsiveness was measured in mice using whole body plethysmography
(Buxco, Sharon, CT, USA). In short, unrestrained, unanaesthetised mice were
placed in a whole-body chamber. Airway responsiveness was measured by
aerosolising increasing concentrations of metacholine (1.6 mg/ml saline to 50 mg/ml
saline, Sigma) for three minutes in the chamber. Airway responsiveness was
expressed as enhanced pause (Penh) (18).
Blood
At several time points (2, 6, 18 or 24 hours) after the last ovalbumin challenge mice
were killed with an overdose of pentobarbital (0.5 g/kg bodyweight). Blood was
retrieved by heart punction. Blood (40 µl) was dissolved in 20 µl heparin (1000
U/ml). This was used for enumerating the number of leukocytes. One drop was
smeared on a slide and stained with Diff Quick (Merz & Dale, Dudingen,
Switzerland) for differential cell counts.
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Broncho-alveolar lavage
A canula was inserted in the trachea. The lungs were lavaged 4 times with 1 ml PBS
(37°C). The fractions were stored on ice. Thereafter, the fractions were centrifuged
for 10 minutes, 300 g. The supernatant of the first fraction was stored at -70°C for
further analysis. The cells of all four fractions were pooled and resuspended 100 µl
phosphate buffered saline (PBS). These cells were enumerated and cytosins were
made. These cytosins were colored with Diff Quick (Merz & Dale, Dudingen,
Switzerland) for differential cell counts.
Lung isolation
Lungs were perfused by injection of 5 ml PBS into the right ventricle of the heart.
Lungs were dissected and stored on ice. One ml of 1.5M KCl was added per 0.10
gram lung tissue. Thereafter, lungs were grained with a mixer and centrifuged at
580g for 10 minutes. The supernatant was stored at -70°C until further analysis.
Eosinophil peroxidase measurement
Samples were diluted once in 0.05 M Tris/HCl. In a 96-wells plate 50 µl sample and
100 µl substrate solution (10 mM o-phenylenediamine dihydrochloride, 4 mM H2O2
in 0.05 Tris/HCL) were added. The plate was incubated at room temperature for 30
minutes in the dark. Thereafter the reaction was stopped with 50 µl 4M H2SO4. The
absorbency was determined at 490 nm.
Eotaxin ELISA
Eotaxin was measured by ELISA using matched-paired antibodies (R&D;
Abingdon, UK). A 96-wells plate was coated with 4 µg/ml capture antibody (100
µl/well) in PBS and incubated overnight. The next day the plate was washed three
times with wash buffer (PBS, 0.05% Tween-20 (sigma), pH 7.4). The wells were
blocked for one hour with 300 µl blocking buffer per well (PBS, 1% BSA, 5%
Sucrose, 0.005% NaN3). The samples were diluted once in assay diluent (tris-
buffered saline, 0.1% BSA, 0.05% tween-20, pH 7.3). One hundred µl of the diluted
samples was pipetted into the wells after washing three times. Also, 100 µl of
standard (1000-15.6 pg/ml human eotaxin R&D in assay diluent) was added. After
two hours of incubation the plate was washed again followed by adding biotinylated
detection antibody (100 µl/well, 180 ng/ml) to the wells. Again, after incubation of
two hours the plates were washed with wash buffer. One hundred µl of
streptavidine-HRP (horseradish peroxidase) (0.125 mg/ml) was added to each well
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and incubated for 20 minutes. Following this, the plate was washed and 100 µl of
substrate solution (reagents A and B, Pharmingen; Heidelberg, Germany) was added
per well. After an incubation period of 20-30 minutes in the dark the reaction was
stopped by adding 50 µl of H2SO4 in each well. The absorbency was read at 450 nm
using a plate reader. The whole assay was performed at room temperature.
Statistical analysis
Data are represented as mean ± SEM (standard error of the mean), unless stated
otherwise. Differences in airway responsiveness were analysed using repetitive
measures ANOVA (analysis of variance) followed by a LSD post hoc test for
multiple comparison. Data were analysed for normal distribution using
Kolmogorov-Smirnov test. Normally distributed data were analysed with a one-way
ANOVA using an LSD post hoc test; otherwise Kruskal-Wallis test was used.
Correlation was demonstrated by way of linear regression. Differences were
considered statistically significant if p<0.05.
Figure 1: Airway responsiveness to methacholine as measured in mice sensitizes with
ovalbumine challenged with saline (Sal, white bars) or ovalbumine (OA, other bars)
treated with rIgG antibodies (Con, gray bars) or antibodies directed against eotaxin (ab,
hatched bars). Challenge with ovalbumin resulted in airway hyper-responsiveness. This
was not blocked with treatment of mice with anti-eotaxin antibodies. Data are represented
as mean (± SEM) (* p<0.05 compared to ovalbumin challenged mice, ANOVA).
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RESULTS
Effect of anti-eotaxin antibodies
To answer the question whether eotaxin is involved in induction of airway
eosinophilia in this model, we treated these mice with neutralizing anti-eotaxin
antibodies. Rat IgG (rIgG) served as control treatment.
Treatment Total cellsa Eosinophilsb EPOc Total IgEd
Sal 17.0 ± 2.30 0.10 ± 0.10 267 ± 96.0 163.8 ± 37.0
OA 55.7 ± 10.2* 49.4 ± 9.6# 309 ± 55.2 1736.0 ± 484.5*
OA + Con 45.0 ± 7.13 29.3 ± 2.9# 389 ± 81.7 1534.7 ± 479.0*
OA + Ab 63.3 ± 13.3** 52.3 ± 6.5# 361 ±26.6 2405.5 ± 482.9**
Table 1: Effect of ovalbumin challenge and antibody treatment on the number of BAL cells,
percentage of eosinophils, eosinophil activation and total IgE. Data are represented as
mean (± SEM). Sal is ovalbumin sensitized mice and challenged with saline. OA are mice
sensitized and challenged with ovalbumin. rIgG was used as a control antibody (Con) and
Ab is used as a neutralizing antibody directed against eotaxin. a x104 cells in BAL fluid; b
percentage of eosinophils in BAL fluid c Eosinophil peroxidase (ng/ml) in lung
homogenates; d Total IgE in ng/ml. (* p<0.05 ** p<0.01compared to saline challenge
(ANOVA). # p<0.01 compared to saline (Kruskal-Wallis) No significant differences were
detectable between ovalbumin challenged groups).
Challenge of sensitized mice with ovalbumin resulted in increased airway
responsiveness compared to mice challenged with saline (p<0.05). Treatment with
antibodies directed to eotaxin did not result in a decrease in antigen-induced airway
responsiveness to methacholine (figure 1).
Treatment 0.5 hours 6 hours 24 hours
Sal-vehicle 4.43 ± 0.88 4.57 ± 0.836 4.14 ± 0.24
Sal-eotaxin 4.52 ± 0.449 4.132 ± 0.831 3.17 ± 0.69
OA-vehicle 7.143 ± 1.640 * 6.13 ± 0.99 * 3.37 ± 0.23
OA-eotaxin 7.443 ± 1.54 * 8.11 ± 1.27 * 7.92 ± 1.92#
Table 2: Airway reactivity to highest dose of methacholine (50 mg/ml) in ovalbumin
sensitized mice challenged with saline (Sal) or ovalbumin (OA) with additional treatment
of intravenous injection of vehicle or eotaxin (500 ng/animal) 24 hours after the last
challenge. At 0.5, 6, and 24 hours airway reactivity was measured. Data are represented
as mean ± SEM (* p<0.01 compared to saline challenged animals, ANOVA on the whole
methacholine curve (1.6-50 mg/ml), # p<0.05 compared to sal challenged animals and
ovalbumin receiving vehicle, ANOVA on maximal response to methacholine (not
significant if whole methacholine curve is considered)).
In addition, the number of cells in the BAL fluid was increased in ovalbumin
challenged mice compared to saline challenged mice. This increase was mainly due
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to an influx of eosinophils (table 1). Treatment with antibodies did not result in a
decreased number of eosinophils. To investigate whether the eosinophils present in
the airways were more activated after ovalbumin challenge, eosinophil peroxidase
(EPO) activity was measured in lung homogenates of these mice. No difference in
EPO activity could be demonstrated in the four different groups of mice (table 1).
As expected an increase in total IgE and ovalbumin specific IgE was measured in
serum of mice challenged with ovalbumin compared to mice challenged with saline
which was not altered by treatment with anti-eotaxin antibody treatment (table 1).
Figure 2: Number of eosinophils in blood and BAL of ovalbumin sensitized mice 24 hours
after eotaxin treatment, and 48 hours after the last challenge with saline (Sal, white or
hatched bars) or ovalbumin (gray or black bars) with an additional treatment with vehicle
(white and gray bars) or eotaxin (500 ng/mouse, intravenously, hatched or black bars).
Challenge with ovalbumin results in increased numbers of eosinophils in blood and BAL.
However, intravenous injection with eotaxin did not increase the number of eosinophils
in these compartments. Data are represented as mean ± SEM. (* p<0.005 compared to
sal-vehicle and sal-eotaxin, ANOVA).
Eotaxin administration
Since eotaxin can activate eosinophils and might therefore influence airway
responsiveness, it was investigated whether an additional dose of eotaxin could
worsen and enhance the asthma-like symptoms induced by ovalbumin. Eotaxin was
administered intravenously to mice 24 hours after the last challenge. Eotaxin
injection did not result in increased airway responsiveness in saline challenged mice
at 30 minutes, 5 hours and 24 hours after eotaxin injection. In addition, airway
hyperresponsiveness in ovalbumin challenged mice was not enhanced by eotaxin
administration (table 2). However, ovalbumin challenged mice were hyper-
responsive compared to saline challenged mice 30 minutes and 5 hours after eotaxin
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administration. Airway hyperresponsiveness was abrogated 24 hours after eotaxin
administration (which is 48 hours after the last ovalbumin challenge). At this time
point ovalbumin challenged mice with an additional injection of eotaxin, had a
tendency for high values of airway responsiveness to methacholine. This might
suggest that eotaxin administration into these mice prolongs the period of airway
hyperresponsiveness. Ovalbumin challenge did not result in significant changes in
blood eosinophils compared to saline challenged mice.
Eotaxin injection did not have an additional effect on the number of eosinophils in
the blood. Although, ovalbumine challenge resulted in increased numbers of
eosinophils in the airways, additional eotaxin treatment did not alter this response
(figure 2).
Eotaxin protein levels
In naïve mice a fair amount of protein was detected in BAL fluid and serum (403 ±
17.1 pg/ml eotaxin, 361 ± 13.6 pg/ml eotaxin, respectively).
Already at 2 hours after the last challenge eotaxin levels were increased in
ovalbumin challenged mice compared to saline challenged mice. This difference got
larger in time at 6 and 18 hours after the last challenge (figure 3).
Figure 3: Increase of eotaxin concentrations in lung homogenates at different time points
(2, 6 and 18 hours) after the last ovalbumin challenge compared to saline challenged
mice. As early as two hours after the challenge eotaxin levels are increased in ovalbumin
challenged mice compared to saline challenged mice. Eotaxin levels in lung homogenates
increased for up to 18 hours after the challenge. At 24 hours the increase in eotaxin levels
decrease compared to 18 hours (* p<0.05, ANOVA). Data are represented as mean ±
SEM. All values were statistical significant compared to saline challenged animals
(p<0.05 Student’s t-test).
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Additionally, twenty-four hours after the last challenge, when ovalbumin challenged
mice display airway hyperresponsiveness and airway eosinophilia, eotaxin levels are
significantly increased after ovalbumin challenge compared to saline challenge
(figure 4).
Figure 4: Eotaxin concentrations in lung homogenates (gray bars) and BAL fluid (black
bars) of mice sensitized with ovalbumin and challenged with saline (Sal) or ovalbumine
(OA). Challenge of mice with ovalbumin resulted in increased levels of eotaxin in both
lung and BAL fluid. Data are represented as mean (± SEM) (*p=0.0085; ** p<0.0001
compared to saline challenged animals, Students t-test).
Later time points were not measured. Serum concentrations were comparable
between saline and ovalbumin challenged mice. There was no correlation in
ovalbumin treated mice between eotaxin concentration in BAL fluid and the number
of eosinophils in the airways or airway responsiveness to methacholine (r2=0.017
(p=0.804); r2=0.051 (p=0.67), respectively; figure 5).
DISCUSSION
Eotaxin is a known chemokine involved in eosinophil trafficking. The objective of
this study was to investigate the role of eotaxin in allergy and airway
hyperresponsiveness. As a tool to investigate this a mouse model for allergic asthma
was used. Mice sensitized with ovalbumin were challenged with saline or ovalbumin
leading to the formation of asthma-like symptoms in ovalbumin challenged mice,
e.g. airway hyperresponsiveness, increased number of eosinophils in the BAL and
production of antigen specific IgE (17). Using this model we demonstrated that (a)
treatment with anti-eotaxin antibodies did not prevent ovalbumin-induced airway
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hyperresponsiveness and lung inflammation, (b) intravenous eotaxin installation did
not worsen or enhance airway pathology although there was a tendency for
prolonged airway hyperresponsiveness in ovalbumin challenged mice after eotaxin
administration, and (c) eotaxin levels were increased in the airways after ovalbumin
challenge.
Figure 5: A No correlation between the number of eosinophils in the BAL fluid and eotaxin
concentrations in the BAL fluid at 24 hours after the last challenge (r2=0.017, p=0.80,
linear regression). B No correlation between eotaxin concentrations in BAL fluid and the
maximal airway response (Emax) to methacholine (50 mg/ml), 24 hours after the last
ovalbumin challenge (r2=0.051, p=0.67, linear regression). Dots represent individual data
points.
Treatment with anti-eotaxin antibodies did not have any effect on eosinophil
migration to the airway lumen, EPO activity, airway hyperresponsiveness, and IgE
production induced by ovalbumin challenge. This might suggest that eotaxin is not
involved in the development of these characteristics in this model. In contrast, other
researchers have shown that anti-eotaxin antibodies were able to reduce airway
eosinophilia in ovalbumin treated mice (19, 20). The ovalbumin model and time and
way of antibody administration used by Gonzalo et al were similar to ours. An
explanation for this contradiction might be that they used a different strain of mice,
C75/bl6. Presumably this strain is more dependent on eotaxin to induce eosinophil
migration.
From recent publications it appeared that eotaxin is involved in eosinophil
recruitment early after allergen challenges and not in later stages. In an ovalbumin
model for allergic asthma antibodies directed against eotaxin resulted in a decreased
eosinophil accumulation in the airways at day four of repeated antigen challenge,
but not at day 7 of ovalbumin challenge. In the same model blocking of monocyte-
derived chemokine (MDC, a CCR4 agonist) resulted in a decreased airway
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inflammation at day 7 and not at day 4, indicating that different stages of eosinophil
recruitment are regulated by distinct chemokines (21). Moreover, in a cutanous
model for allergic reactions eotaxin concentrations correlated with the number of
eosinophils at 6 hours after allergen provocation, while at a later time point other
chemokines were responsible for eosinophil migration (22). This illustrates that
trafficking of eosinophils in response to antigen is a multi-step process in which
more chemokines are involved. In the present study, we looked at eosinophil
recruitment after several allergen challenges. At this time point other chemokines
might have attracted eosinophils to the airways. We did not measure at earlier time
points. Moreover, eotaxin knockout mice have the same number of eosinophils in
their airways after ovalbumin sensitization and challenge compared to their normal
littermate (23). This indicates that other factors contribute to eosinophil migration.
Other chemokines can bind to CCR3. Eosinophils express other chemokine
receptors, for example CCR1, which can be activated by different chemokines. This
redundancy and promiscuity of the chemokine system questions whether blocking
one chemokine or one chemokine receptor is sufficient for abrogating migration of
one cell type.
Although eotaxin can induce eosinophil activation in vitro (14), antigen stimulation
is required for eosinophil activation in vivo (24). In our model ovalbumin challenge
did not result in increased levels of EPO in the airways, indicating that eosinophils
are not increasingly activated after ovalbumin challenge at this time point.
Therefore, eotaxin was administered to see whether an additional effect on the
airways could be obtained. However, this treatment did not result in increased
airway responsiveness and inflammation. This could be another indication that
eotaxin is not involved in both of these parameters. However, these cells might have
released their mediators at earlier stages before the time of measurement.
Importantly, investigating eosinophil degranulation in mice, one has to keep in mind
that mice eosinophils hardly degranulate in response to allergen, in vivo (25).
Although eotaxin is produced under basal conditions, allergen challenge results in
up-regulation of this protein production (26). Our finding is consistent with other
data that have shown before that allergen inhalation results in increased eotaxin
mRNA and protein expression in mice, guinea pigs and humans (19, 27-30). The
increase in eotaxin levels after allergen challenge is a rapid response, since two
hours after the last challenge we detected high eotaxin levels in ovalbumin
challenged mice. In our model, twenty-four hours after allergen challenge eotaxin
concentrations in lung homogenates and BAL fluid were still more then doubled.
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This increase in protein coincides with an influx of eosinophils into the airway
lumen. However, no correlation was observed between eotaxin level and the number
of eosinophils in the BAL fluid or airway hyperresponsiveness, questioning the
function of eotaxin in these two parameters.
The fact that we could not detect a direct correlation between airway responsiveness
and eotaxin levels in the airways at 24 hours after the last challenge might depend
on the time of measurement. In humans, a correlation was found between eotaxin
protein and the level of airflow obstruction at four hours after allergen challenge
(31). Possibly, at earlier time points eotaxin might have correlated with the degree
of airway responsiveness in our animal model. For example, 18 hours after the last
challenge eotaxin levels were maximal increased.
Previously, it was demonstrated that treatment of ovalbumin challenged mice with
anti-IL-5 antibodies completely inhibited airway eosinophilia in this model (32). IL-
5 is a central cytokine regulating eosinophil function; this mediator primes
eosinophils, promotes eosinophil survival and releases precursor cells from the bone
marrow. Eotaxin and IL-5 synergistically act on eosinophils (15). Since we could
not demonstrate an effect of eotaxin in this model, IL-5 might be responsible for
migration of eosinophils (33). Treatment with anti-IL-5 decreased airway
eosinophilia in this model but did not influence airway responsiveness. In contrast,
anti-IFN-γ did not effect the degree of airway inflammation, while airway hyper
responsiveness was completely inhibited (32). This indicates that airway
hyperresponsiveness and airway eosinophilia are two independent processes, which
are differentially regulated.
In conclusion, blockade of eotaxin with anti-eotaxin antibodies did not have any
effect on airway hyperresponsiveness or airway eosinophilia. Additional increase in
eotaxin by installing this protein into the airways did not effect airway eosinophilia,
eosinophil activation or airway responsiveness in both saline and ovalbumin
challenged mice. Furthermore, eotaxin levels were increased in mice sensitized and
challenged with ovalbumin compared to mice challenged with saline. However, this
increase did not correlate with eosinophil migration to the lungs or airway
hyperresponsiveness. From these experiments we conclude that although eotaxin
levels are increased in the airways of mice sensitized and challenged with
ovalbumin, this protein is not involved in airway eosinophilia or airway
hyperresponsiveness.
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SUMMARY
In previous studies we found that guinea pigs demonstrate an increase in airway
reactivity and eosinophil numbers 4 days after a respiratory infection with
parainfluenza-3 virus. Binding of eotaxin to CC-chemokine receptor-3 present on
eosinophils results in eosinophil migration. Therefore, we hypothesised that eotaxin is
involved in eosinophil migration to the airways in virally infected guinea pigs. In this
study, eosinophil numbers were counted in blood and broncho-alveolar lavage fluid and
related with eotaxin concentrations in broncho-alveolar lavage fluid 1, 2, 3 and 4 days
after intratracheal parainfluenza-3 virus administration. On day 1, blood eosinophils
increased by more than 200% (p<0.01). The number of eosinophils were only slightly
enhanced from day 2-4 (40-70%). In contrast, broncho-alveolar lavage fluid eosinophils
were elevated on day 2 (180%) and remained high on days 3-4 (>300%, p < 0.05). This
increase in lung eosinophils corresponded with increased eotaxin levels measured in
broncho-alveolar lavage fluid. This indicates a role for eotaxin in recruitment of
eosinophils to the airways. However, treatment of virally infected guinea pigs with a
CC-chemokine receptor-3 receptor antagonist did not result in a decreased eosinophil
migration to the airways. In conclusion, although eotaxin up-regulation coincides with
increasing eosinophil migration to the airways, blockade of its receptor does not
influence eosinophil trafficking. This indicates that other factors are involved in
eosinophil migration.
INTRODUCTION
Viral respiratory infections can cause airway hyperresponsiveness in healthy humans
and are a frequent cause of exacerbations in asthma patients (1, 2). It has been reported
that 80% of patients with asthma exacerbations tested positive for viral respiratory
infections (3).
Experimental infection with respiratory viruses in human results in increased airway
responsiveness, increased sub-mucosal lymphocytes and epithelial eosinophils, which
seem to persist even after convalescence (4). A correlation exists between changes in
PC20 and changes in the number and activation of eosinophils in sputum in asthma
patients experimentally infected with a respiratory virus (5). Therefore, there might be
a relationship between viral respiratory infections, accumulation of eosinophils in the
lung, and airway responsiveness.
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Chemokines are involved in orchestrating leukocyte migration (6). Recently, the C-C
chemokine eotaxin, discovered in broncho-alveolar lavage (BAL) of guinea pigs
sensitised and challenged with ovalbumin, was found to be a potent eosinophil
attractant (7). Eotaxin induces a selective accumulation of eosinophils when
administered to the airways or injected intradermally (8, 9). The receptor for eotaxin,
CC-chemokine receptor 3 (CCR3), is expressed in high numbers on eosinophils (10)
and also on basophils, Th2 cells, and mast cells (11, 12). The role of eotaxin in the
development of inflammation during allergic reactions is extensively studied. Eotaxin
expression correlates with eosinophil influx in sensitised guinea pigs challenged with
ovalbumin (13). Moreover, an increase in eotaxin levels in BAL fluid from asthmatics
has been observed (14).
In our laboratory an animal model was developed as a tool to investigate the role of
viral respiratory infections on airway inflammation and airway responsiveness.
Therefore, guinea pigs were infected intratracheally with parainfluenza-3 (PI3) virus.
Four days after the initiation of viral infection, guinea pigs expressed airway
hyperresponsiveness to histamine both in vitro and in vivo (15, 16). Furthermore, the
number of BAL cells, especially eosinophils, was increased (17). Airway eosinophilia
and airway hyperresponsiveness was still present 8 and 16 days after infection (16).
In the present study the role of eotaxin in a time course study of airway eosinophilic
influx in guinea pigs treated with PI3 virus was investigated. Migration of eosinophils
was observed and was related to eotaxin levels in BAL fluid. To further investigate the
role of eotaxin in this model, virally infected guinea pigs were treated with a CCR3
receptor antagonist.
METHODS
Animals
Specified-pathogen-free male Dunkin-Hartley guinea pigs (350-450 g, Harlan Olac Ltd,
England) were housed under controlled conditions in cages under filter-tops.
Commercial chow and water were supplied ad libitum. Dutch committee of animal
experiments approved the experiments described in this paper.
Treatment of animals
Viral infection: Animals were treated with PI3 virus as described previously (16). In
short, animals were anaesthetised with halothane. Thereafter, 0.1 ml of the virus
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suspension (ID-DLO, Lelystad, The Netherlands, tissue culture infective dose50 =
108.9/ml) was administered intratracheally. Growth medium was subjected to a similar
procedure in order to serve as a control solution.
Treatment with human recombinant RANTES: In stated experiments guinea pigs were
treated with human RANTES which functions as a CCR3 receptor antagonist in guinea
pigs (18). On days 0 (just before infection), 1, 2, and 3 guinea pigs were injected with
human recombinant RANTES (intraperitoneally, 1.25 µg/kg/day). As a control
treatment guinea pigs were injected with saline. Animals were sacrificed on day 4.
Broncho-alveolar lavage
Animals were sacrificed 1, 2, 3, or 4 days after virus inoculation by an overdose of
Euthesate (sodium pentobarbital, 300 mg/kg). BAL was performed as described
previously (15). From the first 10 ml only 7 ml was retrieved after one minute, and
stored in a plastic tube on ice. After centrifugation 1 ml of cell-free supernatant was
stored for measurement of guinea pig eotaxin with a radio-immuno assay (RIA) as
previously described (13). After recovery of the first 7 ml, the lungs were lavaged 3
times with 10 ml saline. The cells were sedimented by centrifugation at 580 g for 10
minutes at 4°C. Cells were resuspended in 1 ml saline and cytospins were prepared.
Cytospin preparations were stained with Diff Quick (Merz & Dale, Dudingen,
Switzerland) for differential cell counts.
Blood cell differentiation
Blood was obtained by a cardiac puncture. Blood smears were stained with Diff Quick
(Merz & Dale, Dudingen, Switzerland) for differential cell counts. Leukocytes were
enumerated after staining with Turk solution using a heamocytometer.
Statistics
Difference in cell number between guinea pigs treated with virus and medium
treated guinea pigs were tested using a Student’s unpaired t-test. P values < 0.05
were considered statistically different.
Chapter 4
66
RESULTS
Time course study
Blood and BAL eosinophils: Blood and BAL cells were differentiated 1, 2, 3, and 4
days after treatment with PI3 virus (figure 1). One day after virus administration, the
number of eosinophils in peripheral blood was significantly increased by more than
200% (p < 0.01). The percentage of blood eosinophils two, three, and four days after
viral infection was only slightly increased when compared with medium-treated guinea
pigs. In contrast to the observations in blood, BAL fluid eosinophils were not increased
at day 1 after PI3 infections. On day 2 following PI3 virus infection, the percentage of
eosinophils increased by more then 180% and remained significantly elevated on day
3 and 4 (>300%, p < 0.05).
Eotaxin concentrations in BAL: Eotaxin concentrations were measured in BAL fluid
of medium (control) and virus-treated guinea pigs (figure 2). On day 1 eotaxin levels
started to increase. There was a 4-6 fold increase in eotaxin concentrations on day 2-4
(p < 0.05) after viral infection compared to medium-treated animals.
Figure 1: Percentage of eosinophils in blood (black bars) and BAL (grey bars) day 1, 2, 3, and
4 after intratracheal administration of PI3 virus or medium-treated animals (med). Increased
number of blood eosinophils is present at one day after infection compared to medium treated
animals. Significant increased percentage of lung eosinophils is present at day 3 and 4 of
infection. Results are expressed as mean ± SEM * p <0.01, ** p <0.05, compared with
medium-treated animals (student’s T-test).
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Figure 2: Eotaxin concentrations in BAL fluid of guinea pigs on days 1, 2, 3, or 4 after
intratracheal administration of PI3 virus (grey bars) and medium-treated animals (white bar).
Results are expressed as mean ± SEM (n=3-4). Asterisks indicate p<0.05 compared to
medium-treated animals.
Treatment with CCR3 receptor antagonist
Medium or virus inoculated guinea pigs were treated with human recombinant
RANTES that acts as a CCR-3 receptor antagonist in guinea pigs (18). After four days,
the degree of inflammation was assessed. In the BAL fluid of guinea pigs treated with
PI3 virus the number of eosinophils were increased, compared to medium treated
animals (virus treated animals 2.9 x 106±1.38 vs. sham treated guinea pigs 1.4 x
106±0.65 eosinophils). Treatment with human RANTES did not effect the number of
eosinophils in the BAL of virus or medium treated guinea pigs (virus treated animals
2.2 x 106±0.88 vs. sham treated guinea pigs 1.1 x 106±0.15 eosinophils).
DISCUSSION
Infection of guinea pigs with PI3 virus results in airway hyperresponsiveness and an
influx of inflammatory cells, mainly eosinophils (15). The eosinophil influx in the lung
and the degree of airway hyperresponsiveness are associated (17, 19). Therefore, it is
interesting to investigate which mediators are involved in eosinophil trafficking.
From the time course study it appeared that guinea pigs infected with PI3 virus showed
a rapid increase in blood eosinophils. Already at one day after virus infection there was
a marked increase in circulating eosinophils. Two days after infection, eosinophil
numbers decreased again to levels of those observed in medium treated guinea pigs. In
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contrast, eosinophils in the BAL fluid started to increase two days after viral infection.
From this study it appears that eosinophils are rapidly released from the bone marrow
resulting in an increase in blood eosinophils on day one. Thereafter, it seems that these
eosinophils migrate to the airways, eventually ending up in the airway lumen.
There are a number of mediators involved in eosinophil migration. In literature, it is
shown that eotaxin is a potent eosinophil chemo-attractant, which might be a likely
candidate to induce eosinophil trafficking in this model. Therefore, we determined
eotaxin levels in the BAL fluid of guinea pigs at different days of virus infection.
Eotaxin levels were detectable in BAL fluid of medium inoculated guinea pigs. One day
after virus administration eotaxin levels started to increase, and reached significant
higher levels compared to medium treated guinea pigs on days 2, 3, and 4. In view of
the fact that increased eotaxin levels proceeded the increase in BAL eosinophils
indicates that eotaxin might be involved in eosinophil migration.
To investigate whether eotaxin is indeed involved in eosinophil migration guinea pigs
were treated with human RANTES. From previous studies it appeared that human
RANTES acts as a CCR3 receptor antagonist for guinea pig eosinophils, both in vitro
and in vivo. In this study injection of human RANTES into the skin of guinea pigs
resulted in a decreased eotaxin-induced eosinophil migration (18). Treatment of guinea
pigs with human recombinant RANTES blocked the CCR3 receptor in a way that
eotaxin (and other chemokines) can not bind to the CCR3. Nevertheless, in our hands
this treatment did not alter the response of guinea pig toward the virus infection with
respect to eosinophil migration. This might be explained by a redundancy in the
chemokine system. Eosinophils do not only migrate in response to CCR3 agonists, but
activation of other chemokine receptors expressed by eosinophils can cause migration
of these cells as well. RANTES is known to bind to both CCR1 and CCR3. Whether
human RANTES also antagonises CCR1 is unknown. Blocking eosinophil migration
might be more effective if multiple chemokine receptors are antagonised.
The detectable increase in eotaxin levels might be a direct effect of the virus on
epithelial cell without functional implications. It was demonstrated before that viral
respiratory infection result in increased expression of chemokines (20). Human
epithelial cells infected with Influenza A virus expressed higher levels of eotaxin
mRNA and protein compared to non-infected cells (21). This increase in eotaxin
production was induced by the virus itself rather than via an indirect mechanism
involving other inflammatory mediators. Whether the increasing levels in BAL fluid
eotaxin of the present study is caused by de PI3 infection itself or involves other
mediators is not clear.
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Since eotaxin is not involved in eosinophil migration in this model, other mediators
could be candidates to induce eosinophil migration. IL-5 has been shown to be
important in eosinophil migration in many animal models of inflammation. This
mediator displays several actions on eosinophils. It proliferates and differentiates
precursor eosinophils in the bone marrow, it prolongs eosinophil survival, it primes
eosinophils, and it can be directly involved in eosinophil migration (22). In previous
studies it was demonstrated that treatment with antibodies to IL-5 of guinea pigs treated
with PI3 virus did result in a significant drop in blood eosinophils (23). This might
indicate that IL-5 is involved in quickly releasing precursor eosinophils from the bone
marrow into the circulation. Eotaxin was shown to be important in releasing blood
eosinophils into the circulation of guinea pigs, as well. However, this chemokine is
probably not involved in inducing blood eosinophils in our experiments, since blood
eosinophilia existed on day one, while eotaxin levels start to increase at day two of viral
infection. Anti-IL-5 treatment had almost no effect on eosinophil influx into the lung
(23). Moreover, it was shown before that bradykinin was not involved in eosinophil
migration in this model (24).
Since both treatment with antibodies to IL-5 (23) and treatment with anti-eotaxin
antibodies did not result in a decreased airway eosinophilia in virally infected guinea
pigs, it might indicates that the migration of eosinophils is a multi-factorial process,
which is not easily declined. Blockade of only one mediator involved in this cell
trafficking is apparently not sufficient. Treatment that is directed to block multiple stage
in the process of eosinophil migration might be more effective in reducing airway
eosinophilia after a viral respiratory infection.
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SUMMARY
Eotaxin is a chemokine involved in leukocyte migration and acts via the CC
chemokine receptor-3. Recently, it was demonstrated that human mast cells express
this receptor. This study aimed to asses whether murine bone marrow-derived mast
cells express CC-chemokine receptor-3 and whether stimulation of this receptor
with eotaxin results in mast cell degranulation. Bone marrow cells were cultured in
IL-3 containing medium to obtain bone marrow-derived mast cells of the mucosal-
like phenotype. Using flowcytomerty it was demonstrated that bone marrow-derived
mast cells stained positive for CC-chemokine receptor-3 (mean fluorescence
intensity 24), compared isotype control (mean fluorescence intensity 9.73).
However, stimulation of this receptor by eotaxin (10-2000 ng/ml) did not result in
granule exocytosis, as measured by the release of β-hexosaminidase. Although
cross-linking of the IgE receptor by antigen resulted in dose-dependent release of
leukotriene C4, eotaxin did not trigger mast cells to produce this lipid mediator. Due
to environmental differences responsiveness of mast cells can vary between in vitro
and in vivo situations. For that reason, mast cell responsiveness to eotaxin was tested
in vivo. Intravenous injection of mice with 500 ng of eotaxin did not alter mouse
mucosal mast cell protease levels in serum of these mice, indicating that eotaxin
does not activate mast cells in vivo. Collectively, CC-chemokine receptor-3 is
expressed on murine bone-marrow-derived mast cells and stimulation of this
receptor does not result in mast cell degranulation or initiation of leukotriene C4
production, both in vitro and in vivo.
INTRODUCTION
Chemokines are small inducible cytokines involved in leukocyte migration. Eotaxin
is a chemokine acting via the CC-chemokine receptor-3 (CCR3) which is believed
to play a prominent role in eosinophil migration during allergic diseases, such as
asthma (1, 2). During allergic responses eotaxin expression is increased in airways
of asthmatic individuals, resulting in migration of predominantly eosinophils to the
site of inflammation (3). Recently, it was discovered that CCR3 is also expressed by
mast cells (4). Therefore, in addition to the effect on eosinophils, eotaxin might
augment inflammatory reactions by acting on mast cells.
Chapter 5
76
Mast cells play a prominent role in the initiation and development of allergic
diseases, such as asthma (5). Mast cells arise in the bone marrow and travel to
mucosal or submucosal sites where they undergo terminal stages of differentiation.
Cross-linking of membrane-bound IgE by allergen results in activation and
degranulation. Upon activation mast cells release pre-stored mediators, such as
histamine, which is an important initiator of allergic responses. Other than the
release of pre-formed mediators, mast cells activation can also initiate the formation
of arachidonic acid metabolites, or production of pro-inflammatory cytokines. In
this way, mast cells contribute to ongoing, chronic inflammation.
Using immuno-histochemistry and flowcytometry it was demonstrated that a
proportion of human mast cells in skin, gut and lungs express CCR3 (6). In vitro,
CCR3 receptor agonists elicit mast cell migration (6, 7). Furthermore, eotaxin is
involved in differentiation of embryonic mast cells into mature cells (8). Although it
was shown that eotaxin elicited increases in intracellular calcium concentrations in
mast cells (9), activation of these cells by eotaxin has never been demonstrated.
Since mast cells express CCR3 on their surface and eotaxin expression is increased
during inflammation, we speculate that eotaxin augments inflammatory reactions by
directly attracting and activating mast cells. To elaborate on the possible interactions
between mast cells and eotaxin we used bone marrow-derived mast cells (BMMCs)
to study CCR3 expression and functional activity of this receptor in vitro. In
addition, it was assessed whether eotaxin administration in vivo resulted in mast cell
activation.
MATERIALS AND METHODS
Mouse Bone marrow cultures
Conditioned medium: As a growth factor source for the culture of BMMCs
pokeweed mitogen-stimulated spleen cell conditioned medium (PWM-SCM) was
used. This was obtained from spleen cells from BALB/c mice (Charles River).
These were cultured in complete RPMI (RPMI 1640 medium containing 4 mmol/l
L-glutamine, 5x10-5 mol/l 2-mecaptoethanol, 1 mmol/l sodium pyruvate, 100 U/ml
penicillin, 100 mg/ml streptomycine, and 0.1 mmol/l non essential amino acids) plus
10% fetal calf serum (FCS), containing pokeweed mitogen (8 mg/ml, Sigma; St
Louis, USA) at a density of 2x106 cells/ml for seven days in an incubator at 37°C in
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a 5% CO2 humidified atmosphere. After seven days the medium was centrifuged (10
minutes, 400g) and filtered through a 0.45-µm Millipore filter (Corning, USA).
Bone marrow-derived mast cells were cultured as described before (10). In short,
femoral bones were obtained from 8-10 weeks old BALB/c mice. These bones were
aseptically flushed with complete RPMI. The cell suspension was washed twice in
complete RPMI. The cells were cultured at a density of 1x105 cells/ml in complete
RPMI containing 10% (v/v) Fetal Calf Serum (FCS) in an incubator at 37°C in a 5%
CO2 humidified atmosphere. PWM-SCM was added to the culture medium (20%,
v/v). Cells were resuspended in fresh culture medium at a density of 1x105 cells/ml
every week. After 3-6 weeks, mast cells represented >98% of the total cells as
determined by toluidine blue staining.
Immunofluorescent flowcytometry
At 26 days of culture BMMCs were stained with purified rabbit anti-mouse CCR3
polyclonal antibody (Pharmingen, Beckton Dickinson, Heidelberg Germany) for 30
minutes at 4°C. For the isotype control purified rabbit polyclonal antibody Gαi-3
(Pharmingen) was used. This was followed by incubation with anti-rabbit IgG for 30
minutes at 4°C. Staining was done with streptavidin PE (Beckton Dickinson,
Heidelberg Germany) for 30 minutes at 4°C. After each incubation, cells were
washed with phosphate buffered saline (PBS) with 1% (v/v) FCS and 0.01% (w/v)
sodium azide. Samples were analysed using a FACScan flow cytometer (Becton
Dickinson, Heidelberg, Germany).
Mast cell activation
β-Hexosaminidase: BMMCs were cultured for 15 till 20 days under conditions
described above. In stated experiments, approximately 2-3x106 cells were
resuspended in culture medium and incubated with anti-DNP IgE (26.82) for 1 hour
at 37°C, 5% CO2. BMMCs were washed twice with Tyrodes buffer (GIBCO life
technologies, Paisley Scotland) containing 10 mM Hepes (Merck, Amsterdam, The
Netherlands)(pH 7.2) and supplemented with 0.1% (w/v) bovine serum albumin
(BSA, Sigma). The cells were resuspended at a density of 0.6x106 cells/ml,
aliquoted in a 96 wells plates (Costar Corning, NY, USA) (3x104 cells per well), and
activated with eotaxin (10-2000 ng/ml; PBS, 0.1% BSA; R&D Systems, USA) or
DNP-HSA (0.8-25 ng/ml; in case of IgE labelled cells). After 30 minutes,
supernatants from activated cells were collected. Total release of granule content
was established by adding 10 µl 10% (v/v) Triton X-100 (Sigma) per well to get
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complete lysis. Fifty µl of the supernatants were incubated with 4-
methylumbelliferyl glucosaminidine (Sigma) in 0.1 M citrate buffer (0.1 M sodium
citrate (Merck) in bidest, pH 4.5) for 1 hour at 37°C. The reaction was stopped by
adding glycine buffer (0.2 M Glycine (Merck), 0.2 M NaCl (Merck), pH 10.7).
Fluorescence was measured using a multi-well plate reader (Millipore Cytofluor
2350) at an emission wavelength λ=360 nm and excitation wavelength λ=450 nm.
The percentage of degranulation was calculated as: ((a-b)/(t-b))x100, were a is the
amount of β-hexosaminidase released from stimulated cells, b is the β-
hexosaminsidase released from non-stimulated cells and t is total cellular content.
Leukotriene C4 measurements: Cells were stimulated as described above.
Supernatants of 4 wells were pooled for the measurements of leukotriene C4 (LTC4).
This was done using a LTC4 enzyme-immuno assay system (Biotrak, Amersham
Pharmacia biotech, Roosendaal, Netherlands) according to manufacturer’s
instructions.
In vivo mast cell activation
Male BALB/c mice (Charles River) were injected with eotaxin (20 µg/ml PBS,
0.1% BSA, 25 µl/mouse, R&D Systems) or with control solution (PBS/0.1% BSA)
in the tail vein. Thirty minutes after this injection blood was taken by a cardiac
puncture. Blood was placed at room temperature for one hour. Subsequently,
samples were centrifuged and serum aliquots were stored at -20°C. To further assess
mast cell degranulation mouse mucosal mast cell protease-1 and LTC4 were
measured in these serum samples.
Mouse mucosal mast cell protease-1 ELISA
NUNC-immuno plates were coated with 50 µl capture antibody (2 µg/ml, 0.1M
carbonate buffer, pH 9.6) and were incubated for 12-24 hours at 4°C. After rinsing
with wash buffer (PBS/0.05% Tween 20), plates were blocked with 50 µl of 1%
BSA in PBS/0.05% Tween 20 for thirty minutes at 4°C. Thereafter plates were
washed with wash buffer and 50 µl of standard (4-0.25 ng/ml) and samples (diluted
in 4% BSA in PBS/0.05% Tween 20) were loaded into the wells. Plates were
incubated for 24 hours at 4°C. After washing, conjugate (streptavidine-HRP
1:10.000) was added to each well (50 µl/well) for 2 hours at 4°C. Plates were
washed with wash buffer. To obtain colour development, 50 µl OPD/H2O2 (5 mg o-
phenylenediamine dihydrochloride (Sigma) in 11ml PBS and 5µl H2O2) was added
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for 30 minutes at room temperature. The reaction was stopped by 2.5M H2SO4 (25
µl/well). Optical density was measured at 490 nm.
Statistics
Data are represented as mean ± SEM (standard error of the mean). Differences were
analysed using Student’s t-test.
RESULTS
CCR3 expression by BMMCs
Development of mast cells from bone marrow cells was assessed by toluidine blue
staining and flow-cytometric analysis for the expression of FcεRI and CD117 (data
not shown (10)). Fully maturated BMMCs were analysed for CCR3 by flow
cytometry. As shown in figure 1, BMMCs showed moderate expression of CCR3 on
their cell surface.
Figure 1: CC-chemokine-3 expression on bone marrow derived mast cells. Grey histogram
represents the non-stained cells (mean fluorescence intensity 3.75). Black dotted line
represents isotype control cells (mean fluorescence intensity 9.73) and the black line are
cells stained with CCR3-PE (mean fluorescence intensity 24).
BMMC in vitro activation
β-Hexosaminidase release: β-hexosaminidase release of mast cells was used as a
tool to measure mast cell granule exocytosis. To assess whether CCR3 activation on
BMMCs could lead to mast cell degranulation, cells were incubated with increasing
concentrations of eotaxin. Stimulation of BMMCs with eotaxin (10-2000 ng/ml) did
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not resulted in significant release of β-hexosaminidase (table 1), while stimulation
of the IgE receptor with IgE and antigen (0-33 ng/ml DNP-HSA) resulted in a dose
dependent release of β-hexosaminidase.
LTC4 production: In addition to granule exocytosis mast cells are able to produce
arachidonic acid metabolites after stimulation. To investigate whether eotaxin is
able to initiate LTC4 production, BMMCs were stimulated with eotaxin or antigen.
Antigen stimulation resulted in a dose dependent release of LTC4 under all culture
conditions. However, eotaxin did not induce production of LTC4 (figure 2).
In vivo mast cells activation
In order to test whether eotaxin could activate mast cells in vivo, mice were injected
with eotaxin (500 ng/mouse), and thirty minutes later mast cell activation
Treatment
Concentration
(ng/ml)
Degranulation (%)
Eotaxin 0 0.0 (± 0.121)
100 0.485 (± 0.254)
500 0.242 (± 0.360)
1000 -0.307 (± 0.272)
2000 0.081 (± 0.116)
DNP-HSA 0 0.0 (± 0.121)
1.2 10.96 (± 1.372)
3.7 18.49 (± 2.803)
11 30.15 (± 3.072)
33 32.48 (± 2.326)
was assess by measuring mucosal mast cells protea
for mast cells activation. Treatment with eotaxin di
this protein (eotaxin: 5.72 ± 0.746 ng/ml, control: 5
addition, no significant changes in LTC4 levels wer
treated with eotaxin (eotaxin 79.29 ± 38.1 pg LTC4
p=0.249).Table 1: Percentage of β-hexo-
saminidase release by BMMCs in
response to eotaxin (0-2,000 ng/ml)
or DNP-HSA (0-33 ng/ml). Data is
represented as mean of 4 wells (±
SEM).se-1 in serum, which is a marker
d not result in increased levels of
.64 ± 0.859 ng/ml; p=0.933). In
e present in serum of mice
, control: 132.0 ± 19.8 pg LTC4;
Mast cells express CCR3
81
Figure 2: Stimulation with DNP-HSA (0.8, 3.1 and 25 pg/ml) resulted in increased
production of LTC4 by BMMCs. Stimulation with eotaxin does not induce production of
LTC4. Data are represented as mean (± SEM) of quadruplicates.
DISCUSSION
In this study we report that BMMCs express CCR3 on their surface. Other studies
showed before that human mast cells in skin, gut, and lung tissue express this
receptor (6, 11). To assess the functional properties of CCR3, BMMCs were
stimulated with eotaxin, a potent ligand of the CCR3 receptor. Increasing
concentrations of eotaxin do not lead to granule exocytosis by BMMCs. These
results are concordant with other studies, showing that eotaxin does not induce mast
cells activation. Human mast cells isolated from lungs do not release histamine after
stimulation with eotaxin (11). Moreover, RANTES, which binds to both CCR1 and
CCR3, does not induce histamine or β-hexosaminidase release by BMMCs (7).
Although other studies have looked at mast cell exocytosis by eotaxin, our study is
the first to investigate whether stimulation with eotaxin leads to the production of
arachidonic acid metabolites. Previous studies in our lab showed that BMMCs are
capable of producing lipid mediators, also after non-immunological stimuli (12).
Leukotrienes are potent bronchoconstrictors, and are involved in the pathology of
asthma. However, no LTC4 formation can be detected after stimulation of BMMCs
with eotaxin.
Other chemokines can activate mast cells leading to mast cell exocytosis. For
example, monocyte chemotactic protein-1 (MCP-1), a ligand for CCR2, can dose-
dependently induce histamine and serotonin release from rat peritoneal and
pulmonary mast cells in vitro (13, 14). Surprisingly, the same dose of MCP-1 does
Eotaxin (ng/ml) DNP-HSA (ng/ml)
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not lead to activation of BMMCs. This may reflect maturational differences between
different population of mast cells resulting in altered responsiveness of these cells.
In the present study we used BMMCs which are often used as a tool to investigate
mast cell activation in vitro. Different culture conditions influence the maturation of
mast cells and alter the responsiveness of these cells (12). In vivo, the
microenvironment is different from in vitro circumstances. Therefore, in the present
study the effect of eotaxin on mast cell activation is tested in vivo. No increase in
mouse mucosal mast cell protease-1 levels in serum of mice injected with eotaxin
could be detected, questioning the role of CCR3 in mast cell activation. In contrast,
instillation of MCP-1 into the lungs of mice results in increased levels of histamine
in the airway (14). This indicates that stimulation of CCR2 leads to mast cell
stimulation while stimulation of CCR3 does not.
A rise in intracellular calcium concentrations was measured after stimulation of
mast cells in response to eotaxin indicating that mast cells become activated after
stimulation of the CCR3 (9), but this activation does not lead to degranulation or
LTC4 production. Binding of CCR3 ligands to the receptor results in activation of
eosinophils and basophils, leading to the formation of various cytokines (15, 16).
This might suggest that the signal transduction cascade is differently regulated in
mast cells compared to eosinophil and basophils.
However, activation of CCR3 might lead to migration of mast cells. Indeed, CCR3
ligands are involved in mast cell migration in vitro (6, 7, 11). Both eotaxin and
RANTES act as a chemoattractant for mast cells in a chemotaxis assay. Eotaxin is
expressed under non-inflamed conditions and may therefore contribute to basal
tissue homing of mast cells. Increased expression of eotaxin during inflammation
can be the cause of increased numbers of mast cells in these conditions. For
example, elevated numbers of mast cells are demonstrated in the lungs during the
late phase reaction in asthma (17). In contrast, eotaxin injection in vivo leads to
accumulation of mainly eosinophils at the site of injection and not mast cells. At the
time of an inflammatory response other mediators might be formed which alter the
responsiveness of mast cells.
Mast cells are involved in eotaxin-induced eosinophil migration. Eotaxin-induced
eosinophil migration in vivo is dramatically decreased in absence of mast cells or
stabilised mast cells (18, 19). These studies illustrate that activated mast cells have a
profound function in eotaxin-induced eosinophil migration. Since direct mast cell
activation in response to eotaxin is not demonstrated, the effect of mast cells in this
process is likely to be indirect.
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Another function of eotaxin might be its involvement in differentiation of mast cells
(8). Mast cell precursors arise in the bone marrow and migrate to tissue where they
undergo terminal differentiation into mucosal (tryptase positive cells in humans) or
connective tissue type (tryptase/chymase positive cells in humans) cells. The final
differentiation in one type or other type of cell depends on the microenvironment in
the tissue. Human mast cells, which are chymase tryptase positive, primarily express
CCR3 compared to tryptase positive cells (6). In the present study we used BMMCs
cultured with IL-3 containing medium, which evolve into mucosal-like mast cells.
Culturing BMMCs in the presence of IL-4 and SCF gives rise to connective tissue-
type mast cells. This type of mast cell did not respond to eotaxin either (data not
shown).
This study showed that CCR3 is present on murine BMMCs. Activation of this
receptor by eotaxin does not result in mast cell degranulation or production of LTC4.
Although eotaxin does not activate mast cells directly, attraction of these cells to the
site of inflammation may be important in enhancing inflammatory conditions.
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SUMMARY
Eotaxin is a chemotactic cytokine, which is involved in eosinophil trafficking. This
study aimed to assess the effect of eotaxin inhalation on migration of eosinophils to
the airways. In this randomised placebo-controlled crossover trial, 5 mild asthmatic
and 5 non-asthmatic volunteers were asked to inhale 20 µg of eotaxin. The effect of
this treatment on sputum eosinophils, circulating eosinophils, airway reactivity to
methacholine (PC20), exhaled nitric oxide and carbon monoxide, and sputum eotaxin
concentrations was determined for up to 72 hours after inhalation. Sputum was
induced before inhalation and 5, 24 and 72 hours after inhalation. At five hours,
increased concentrations of eotaxin were measurable in sputum. At the same time, a
significant increase (1.7 fold) in sputum eosinophils was detectable in asthmatic
volunteers. Changes in sputum eosinophils after eotaxin inhalation almost reached
significance compared to placebo inhalation. Interestingly, prior to the increase in
sputum eosinophilia, there was a significant drop in circulating eosinophils.
Treatment with eotaxin did not effect PC20 or exhaled nitric oxide and carbon
monoxide. In contrast to asthmatic subjects, no influx of eosinophils to sputum was
detectable in non-asthmatic volunteers. This might be due to increased numbers and
responsiveness of eosinophils in asthmatics. Thus, increased eotaxin levels in the
airways might cause trafficking of eosinophils from the circulation to the airway
lumen in mild asthmatic patients but not in healthy subjects.
INTRODUCTION
Eotaxin is a member of the CC-chemokine sub-family (1), and binds selectively to
the CC-chemokine receptor-3 (CCR3) (2), which is expressed on eosinophils,
basophils, Th2 cells and mast cells (2-5). Eotaxin is involved in migration and
activation of these cell types. In several animal models it has been shown that
eotaxin is involved in eosinophil trafficking. Injection of eotaxin into the skin or
airways of guinea pigs results in migration of eosinophils to the site of injection (1,
6). In the airways eotaxin is mainly produced by epithelial and endothelial cells (7,
8) after stimulation with pro-inflammatory cytokines, including interleukin (IL)-1,
IL-4 and tumour necrosis factor-α. (7, 9).
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Since eotaxin acts on eosinophils, basophils, Th2 cells, and mast cells which are key
effector cells involved in asthma, it is believed that eotaxin might be important in
the pathophysiology of this disease. Indeed, increased expression of eotaxin mRNA
in the airways of asthmatic patients was demonstrated (10-12). In asthmatic patients,
sputum eotaxin levels positively correlate with the number of eosinophils present in
the airways and the severity of the disease (12, 13). Taken together, it is likely that
eotaxin is involved in the pathophysiology of asthma.
Therefore, in this study we investigated whether eotaxin inhalation resulted in
airway eosinophilia, a characteristic feature of asthma. In this double blind, placebo-
controlled, crossover study, mild asthmatic and non-asthmatic volunteers inhaled a
single dose of eotaxin. The primary objective of this study was to assess the effect
of this treatment on the number of eosinophils in sputum and in the circulation.
Also, the degree of airway inflammation was determined by measuring exhaled
nitric oxide (NO) and carbon monoxide (CO). Furthermore, to investigate whether
eotaxin is involved in inducing airway hyper-responsiveness, lung function
parameters were measured.
MATERIALS AND METHODS
Patients
Five (4 female) atopic mild asthmatic (age range 23-45) and 5 (2 female) non-atopic
non-asthmatic (age range 25-46) volunteers participated in this study (see table 1 for
patients characteristics). All were non-smokers. Non-asthmatic volunteers did not
have a history of respiratory diseases. All mild asthmatic volunteers had a history of
chest tightness and wheezing. They used β2-receptor agonist as needed, but had not
used steroid treatment for at least four weeks prior to the start of the study. None of
these volunteers had suffered from a respiratory infection four weeks prior to the
study. Their FEV1 (force expiration volume in 1 second) was >70% predicted.
Additionally, airway responsiveness to methacholine (PC20) in asthmatics was < 8
mg/ml while non-asthmatics had a PC20 of > 16 mg/ml methacholine. All volunteers
signed an informed consent and the protocol was approved by the ethics committee
of the Royal Brompton Hospital.
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Subject A/NA Sex Age FEV1
(%pred)
PC20
(mg/ml)
Sputum
eosinophils
(%)
NO
(ppb)
1 NA F 26 91.4 64 0.67 4
2 A F 38 93.4 1.5 0.0 73.8
3 NA M 26 77.7 64 0.17 17.5
4 A M 27 90.9 0.45 0.83 37
5 NA F 46 74.3 64 1.7 10.6
6 A M 29 90.8 0.69 0.0 4.7
7 NA F 25 95.2 64 0.0 4.6
8 A F 24 90.0 0.22 0.17 47.9
9 NA F 23 95.0 64 0.17 17.3
10 A M 24 84.4 4.6 1.5 78.2
Mean
(SEM)
A 2 F
3 M
23.7
(2.6)
89.9
(1.5)
0.54*
(1.4#)
0.50
(0.15)
48.3
(14.9)
Mean
(SEM)
NA 4 F
1 M
29.2
(4.7)
87.1
(4.1)
64*
(0.0#)
0.53
(0.31)
10.8
(3.3)
Table 1: Characteristics of asthmatic (A) and non-asthmatic (NA) volunteers and their
FEV1 (% predicted), PC20 (mg/ml methacholine), precentage of sputum eosinophils and
exhaled NO (parts per billion). * Geometric mean, # Geometric standard error of the mean.
Study design
The study was designed as a double blind, randomised placebo-controlled, crossover
study. The study continued over a period of three weeks. Baseline sputum cells and
PC20 were determined in the week before start of the study. Baseline FEV1, NO/CO
measurements were done at the start of the study. In the first and third week, either
eotaxin (R&D, 20 µg/2 ml saline 0.1% HSA) or placebo was inhaled for 5-10
minutes using a nembulizer (MEDIC-AID, Pagham, UK). Thereafter, the
nembulizer was flushed with saline to ensure all the eotaxin was inhaled. FEV1,
blood eosinophils, exhaled NO/CO were determined at 0.5, 1, 2, 3, 4, 5, 24, and 72
hours after inhalation. Sputum was induced and PC20 to methacholine was measured
at 5, 24, and 72 hours after the inhalation. Week two was considered as a washout
period.
Sputum
Induction: Fifteen minutes prior to sputum induction asthmatic volunteers inhaled
200 mg Salbutamol. To induce the sputum patients inhaled 3.5 % saline solution for
15 minutes using a nembulizer (DeVilbiss Ultraneb 2000). Before sputum induction
and before coughing up sputum patients were asked to spit saliva into a bowl and
rinse their mouth with water to avoid saliva contamination. Sputum produced in the
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first 5 minutes was regarded as an unsuitable sample. Sputum produced in the last
10 minutes was coughed up into a tube.
Processing: Part of the sputum sample was kept aside for eotaxin ELISA. This part
of the sputum was weighted and dissolved in cold TFA buffer. Samples were stored
at -20°C. The remainder of the sputum sample was used for cell differential
analyses. Therefore, 0.25 ml 0.1% DTT (1,4-Dithio-DL-threitol; Sigma, St Louis,
USA) was added. The sputum was made homogenous by repeated agitation of the
sample. The sample was diluted with Hanks Balanced Salt Solution (HBSS, Sigma)
to make up a volume of 5 ml bringing the final DTT concentration to 0.005%. The
sputum was centrifuged (300g, 10 minutes), and supernatant was stored in -70°C.
Cells were washed once with HBSS and cell pellet was resuspended in 1 ml HBSS.
The number of cells was counted using a haemocytometer and kimura stain.
Viability was assessed using trypan blue. Cytospins (Shandon, 6 minutes, 600 rpm)
were made with 20,000 inflammatory cells per slide. Slides were stained with Diff-
Quick (Merz & Dale, Dudingen, Switzerland). Differential cell counts were made
from 2 slides per sample by counting 300 inflammatory cells per slide. A sample
was considered to be inadequate if the percentage of squamous cells was > 80%.
Circulating eosinophils
Blood eosinophil counts were determined by the haematology department of the
hospital using an automated haematology analyser (Advia, UK).
Lung function parameters
FEV1: Forced expiratory volume in 1 second was measured using a spirometer
(Vitallograph, Buckingham UK). The better of two attempts was recorded.
PC20: fall of 20% of FEV1 to methacholine was measured as described previously
(14). Increasing doubling doses of methacholine (0.06-64 mg/ml) were administered
via a dosimeter (Mefar, Bovezzo, Italy). Each concentration was inhaled five times
for one second followed by 6 seconds non-breathing time. Two minutes after each
dose FEV1 was measured. PC20 was recorded as the concentration of methacholine
resulting in a drop of FEV1 by 20% compared to FEV1 after saline inhalation. The
PC20 value was calculated by interpolation of the logarithmic dose-response curve.
Exhaled nitric oxide and carbon monoxide
Exhaled nitric oxide (NO) and carbon monoxide (CO) was measured by a
chemiluminescence breath analyser (Logan research, Rochester UK). Patients were
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asked to take a deep breath in through their mouth and breathing out steadily
maintaining constant exhalation flow for as long as possible (at least 20 seconds).
Measurements were taken at the end of exhalation (15).
Mediator analyses
Eotaxin ELISA: Eotaxin was measured by ELISA using matched-paired antibodies
(R&D, Abingdon, UK). A 96-wells plate was coated with 4 µg/ml capture antibody
(100 µl/well) in phosphate buffered saline (PBS) and incubated overnight. The next
day the plate was washed three times with wash buffer (PBS, 0.05% Tween-20
(Sigma, Dorset, UK), pH 7.4). The wells were blocked for one hour with 300 µl
blocking buffer per well (PBS, 1% BSA (bovine serum albumin), 5% Sucrose,
0.005% NaN3). The samples were diluted once in assay diluent (tris-buffered saline,
0.1% BSA, 0.05% tween-20, pH 7.3). One hundred µl of the diluted samples was
pipetted into each well after washing three times. Also, 100 µl of standard (1000-
15.6 pg/ml human eotaxin in assay diluent) was added. After two hours of
incubation the plate was washed again followed by biotinylated detection antibody
(100 µl/well, 180 ng/ml). The limit of detection for this assay is 10 pg/ml. Again,
after incubation of two hours the plates were washed with wash buffer. One hundred
µl of streptavidine-HRP (0.125 mg/ml) was added to each well and incubated for 20
minutes. Accordingly, the plate was washed and 100 µl of substrate solution
(reagents A and B, Pharmingen) was added per well. After an incubation period of
20-30 minutes in the dark the reaction was stopped by adding 50 µl of H2SO4 in
each well. Absorbence was measured at 450 nm using a plate reader. The whole
assay was performed at room temperature.
Eosinophilic cationic protein radio-immuno assay: A kit was purchased from
Pharmingen (Heidelberg, Germany). The measurements were done according to the
manufacturer’s instructions.
Statistics
Data are represented as individual data points or as mean ± SEM. Differences were
analyzed using the Wilcoxon paired signed rank test. Between group differences
(active vs placebo) were analyzed using the Mann-Whitney U-test. A sample size
calculation was performed (16). We assumed that a difference of 0.5% is relevant.
Sample size calculations showed that we need to include at least six individuals to
detect such a difference in our study with 80% power, given a type 1 probability of
0.05%.
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RESULTS
Sputum cells
The average percentage eosinophils of total cell number in sputum at baseline was
0.51 ± 0.29 in asthmatic volunteers, and 0.53 ± 0.31 in healthy subjects (table 2). In
the asthmatic group, eotaxin inhalation resulted in significantly increased
eosinophils in sputum after five hours (1.1 ± 0.30, p=0.031) (figure 1).
At this time point, changes in sputum eosin
increase compared to placebo inhalation (p
72 hours after eotaxin inhalation no chang
compared to baseline sputum levels (24h: 0
Time (h) A-eotaxin A-placebo
B 0.50 ± 0.29 0.50 ±0.29
5 1.07 ± 0.30 * 2.13 ± 1.1
24 0.47 ± 0.15 1.42 ± 0.86
72 0.93 ± 0.23 0.43 ± 0.11
Table 2: Sputum eosinophils (% of total leuko
(NA) volunteers. Sputum eosinophils were 
after eotaxin or placebo inhalation. Data 
compared to baseline values (Wilcoxon paire
changes after placebo inhalation. Differen
asthmatic patients after eotaxin or placeb
p=0.055 (Mann-Whitney U test).
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*Figure 1: Percentage of eosinophils in sputum
at baseline and 5 hours after eotaxin
inhalation in asthmatic subjects. There is an
increased percentage of sputum eosinophils
5 hours after eotaxin inhalation compared to
baseline (b) levels (*p=0.031, Wilcoxon
paired signed rank test).ophils after eotaxin inhalation tended to
=0.055). In asthmatic volunteers, 24 and
es in sputum eosinophils were detectable
.47 ± 0.15, 72h: 0.93 ± 2.3; table 2).
NA-eotaxin NA-placebo
0.53 ± 0.293 0.53 ± 0.31
0.90 ± 0.78 0.17 ± 0.13
0.358 ± 0.19 0.23 ± 0.233
0.633 ± 0.40 0.40 ± 0.16
cytes) in asthmatic (A) and non-asthmatic
determined before (b), 5, 24 and 72 hours
are expressed as mean ± SEM. *p=0.031
d signed rank test). There are no significant
ces in changes in sputum eosinophils in
o inhalation almost reached significance
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In the non-asthmatic non-atopic group no significant changes in sputum eosinophils
were present at any time point after eotaxin inhalation (table 2)
The percentage of neutrophils increased in both groups following both eotaxin and
placebo (figure 2). After eotaxin inhalation the percentage of neutrophils in sputum
increased from 25.03 ± 4.83 to 39.53 ± 6.23 at 24 hours. After placebo treatment a
similar increase in neutrophils was detected (24 hour: 40.44 ± 2.85). No significant
changes in lymphocytes and macrophages were noticeable (data not shown).
Figure 2: Percentage of sputum neutrophils after eotaxin (black squares) or placebo (open
squares) inhalation. A clear neutrophilia was present 24 hours after eotaxin and placebo
inhalation compared to baseline (b) levels. Data are represented as mean ± SEM.
Circulating eosinophils
Three and four hours after eotaxin inhalation a decrease in blood eosinophils was
detectable (baseline: 0.25 ± 0.057, three hours: 0.19 ± 0.041 p=0.013, four hours:
0.16 ± 0.041 p=0.042). This decrease was not evident after placebo inhalation (table
3).
Eotaxin concentrations
Eotaxin was measured in sputum samples not treated with DTT and in plasma
samples at different time points after inhalation. Sputum eotaxin levels were
measured in 5 volunteers after eotaxin inhalation. In three of these samples eotaxin
levels increased at 5 hours and returned to baseline levels at 24 hours. In two of the
5 patients eotaxin was undetectable (figure 3).
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Time (hours) Eotaxin Placebo
Basal 0.26 ± 0.050 0.22 ± 0.033
0.5 0.26 ± 0.044 0.20 ± 0.030
1 0.233 ± 0.055 0.20 ± 0.043
2 0.21 ± 0.035 0.20 ± 0.39
3 0.19 ± 0.041* 0.15 ± 0.037
4 0.17 ± 0.040** 0.18 ± 0.032
5 0.19 ± 0.041 0.21 ± 0.039
24 0.22 ± 0.033 0.23 ± 0.036
72 0.22 ± 0.039 0.22 ± 0.042
Table 3: Number of blood eosinophils (109/ml) at several time points after inhalation of
eotaxin or placebo. At 3 and 4 hours after eotaxin inhalation a decrease in circulating
eosinophils in observed (*p=0.0133, **p=0.0431 compared with baseline values (paired t-
test)) which is not present after placebo inhalation. Data are represented as mean ± SEM
Figure 3: Eotaxin concentration (pM/g sputum) in sputum after eotaxin inhalation in five
volunteers. A marked increase in sputum eotaxin concentrations is detectable in three
patients. In the other two patients the eotaxin concentration was below detection limit.
Data are represented as mean ± SEM.
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Eosinophil activation
Eotaxin is also able to activate eosinophils; therefore we measured eosinophilic
cationic protein (ECP). ECP is released by eosinophils upon activation. In asthmatic
patients no significant changes were observable after eotaxin inhalation (baseline:
20.7 ± 7.0, 5 hours: 20.9 ± 4.2, 24 hours: 17.6 ± 4.9, and 72 hours: 10.8 ± 3.6)
(figure 4).
Exhaled NO/CO
Exhaled NO and CO are increased in asthmatics patients and have been utilised as
non-invasive markers of inflammation. We hypothesised that eotaxin inhalation
would result in increasing levels of exhaled NO and/or CO. Indeed, baseline exhaled
NO concentrations were increased in asthmatic volunteers compared to non-
asthmatic volunteers (figure 5). Exhaled CO did not differ at baseline between the
two groups. However, no significant changes in exhaled NO and CO were
detectable after treatment with eotaxin.
Figure 4: Eosinophil cationic protein (ECP) concentration per ml sputum at baseline, 5, 24,
and 72 hours after eotaxin inhalation. No significant changes were detectable.
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Lung function
The average baseline airway responsiveness to methacholine in asthmatic volunteers
was 2.33 ± 1.10 mg/ml compared to more than 64 mg/ml methacholine in non-
asthmatic volunteers. To investigate whether eotaxin has a direct or indirect effect
on lung function, PC20 was determined at 5, 24, and 72 hours after treatment. The
results show that eotaxin or placebo inhalation did not alter logPC20 values (table 4).
Inhalation of eotaxin did not effect FEV1.
Asthmatics Non-asthmatics
Time Placebo Eotaxin Placebo Eotaxin
5 -5.97 ± 27.7 6.12 ± 28.7 -4.90 ± 4.35 -15.1 ± 11.7
24 10.5 ± 14.5 5.76 ± 5.80 0.0 ± 0.0 -0.941 ± 1.05
72 24.2 ± 19.0 10.7 ± 17.6 0.0 ± 0.0 -7.78 ± 6.84
Table 4: Changes (%) in airway reactivity to methacholine (log PC20) in asthmatics
after treatment with eotaxin or placebo. No significant changes were detectable
after treatment with eotaxin or placebo. Data are represented as mean ± SEM.
Figure 5: Exhaled NO (ppb) (A) and CO (ppm) (B) at several time points (baseline,
0.5, 1, 2, 3, 4, 5, 24, 72 hours) after eotaxin inhalation in asthmatics (closed
circles) and non-asthmatics (open circles). No significant changes were detectable
in exhaled gases after eotaxin inhalation.
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DISCUSSION
This is the first study to show that eotaxin inhalation results in increased relative
number of sputum eosinophils in mild asthmatic patients. Five hours after eotaxin
inhalation the percentage of sputum eosinophils was almost doubled compared to
levels of baseline sputum eosinophils in asthmatic volunteers. The increase in
sputum eosinophils in the mild asthmatic group was transient, since 24 and 72 hours
after eotaxin inhalation the percentage of sputum eosinophils returned to baseline
levels. After placebo inhalation there were no changes in sputum eosinophils. At
three and four hours after eotaxin inhalation, just before the increase in sputum
eosinophils, a decrease in circulating eosinophils was observed. This might indicate
that eosinophils from the circulation migrate to the airways.
The pattern of eosinophil influx corresponds with eotaxin concentrations measured
in sputum. At five hours after eotaxin inhalation increased eotaxin concentrations
were measurable in sputum supernatant. At 24 hours after inhalation eotaxin levels
in sputum were comparable to baseline values. An explanation for this transient
increase in eotaxin concentrations might be that after a while eotaxin is broken
down by proteases in the airways, or eotaxin is diffused further into the lungs. From
this study it appears that eotaxin inhalation results in increased eotaxin levels in
sputum 5 hours after eotaxin inhalation. As a result eosinophils migrate from the
circulation to the airways, leading to in decreased number of blood eosinophils prior
to increased sputum eosinophils.
Since asthmatic patients have an increased expression of eotaxin in their airways,
eotaxin is believed to be involved in inflammation during asthma. Increased eotaxin
levels were measured in sputum, and broncho-alveolar lavage fluid of asthmatic
patients. Increased eotaxin levels in sputum correlate with the percentage of sputum
eosinophils, (12). Allergen challenge induced eotaxin production and correlated with
the number of eosinophils to in the BAL fluid (17). Our results also indicate that
eotaxin is involved in airway inflammation, since increasing eotaxin concentrations
in sputum trigger eosinophils to migrate to the airways, where high concentrations
of eotaxin are present.
Sputum induction is a non-invasive way to determine the number of inflammatory
cells in the lungs. Since the number of eosinophils in sputum correlates well with
the number of eosinophils in bronchial biopsies (18), sputum is a well-accepted
method of assessment of airway inflammation. In this study, 24 hours after eotaxin
or placebo inhalation a prominent neutrophil influx was present in the sputum.
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Repetitive sputum induction, as done in the present study, is known to cause
excessive neutrophil migration to the sputum (19).
Basal sputum eosinophils did not differ between mild asthmatic and non-asthmatic
patients in this study. Interestingly, inhalation of eotaxin by non-asthmatic
volunteers did not result in changes in sputum eosinophils as seen in mild asthmatic
volunteers. It has previously been observed that a proportion, but not all, of
asthmatic patients have increased serum levels of IL-5 (20). This cytokine is known
to enhance responsiveness of eosinophils to eotaxin by priming these cells (21).
Intravenous IL-5 administration to humans induced peripheral mobilization of
eosinophils without effecting lung eosinophils and airway responsiveness (Van
Rensen, Thorax, 2001 in press). Furthermore, intravenous administration of IL-5 in
humans mobilizes eosinophil progenitor cells and induces up-regulation of CCR-3
(Stirling, AJRCCM 2001, in press). Therefore, the fact that mild asthmatic
volunteers responded to eotaxin inhalation while non-asthmatic participants did not,
may be explained by the degree of eosinophil priming, which may well be less in
non-asthmatic subjects due to low levels of IL-5.
It has been shown before that eotaxin is able to induce eosinophil migration in
humans (22). In a clinical trial, eotaxin was instilled in the nose of rhinitic
volunteers. Comparable to our study, eotaxin application resulted in eosinophil
accumulation in nasal lavage fluid. Additionally, nasal symptom score and nasal NO
were increased after treatment with eotaxin. Although previous investigators have
shown correlation of exhaled NO with the number of eosinophils in the sputum (23),
in the present study no changes in exhaled NO were measured after eotaxin
inhalation. Certainly the influx of eosinophils into the airways was of low
magnitude and may have been too low to induce changes in exhaled NO. Further,
nasal application of eotaxin might be more efficient in inducing eosinophil influx
since the nasal cavity is smaller then the lungs.
The role of eosinophils in inducing airway hyper-responsiveness is still unresolved.
In this study eotaxin inhalation resulted in increased levels of eosinophils in the
lungs, while bronchial responsiveness to methacholine was unchanged. This might
demonstrate that in this case there is no association between airway responsiveness
and airway eosinophilia. Recently, evidence accrued to suggest dissociation between
airway eosinophilia and airway hyper-responsiveness. In a clinical trial of anti-IL-5
antibody in asthma, anti-IL-5 treatment abrogated airway eosinophilia after allergen
challenge while airway hyper-responsiveness was unchanged (24) indicating that the
eosinophils in the airways do not correlate with airway responsiveness.
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In conclusion, eotaxin inhalation into the airways of mild asthmatic patients was
associated with augmented levels of eotaxin in sputum supernatant, and resulted in
an increase in relative eosinophil numbers in sputum five hours after inhalation. A
significant drop of circulating eosinophils was observed prior to the increase in
airway eosinophils, suggesting that eosinophils migrate from the circulation into the
airways due to increased eotaxin levels in sputum. This study lends further weight to
the suggestion that eotaxin and/or its receptor CCR3 may be suitable targets for anti-
asthma therapies.
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INTRODUCTION
After the discovery of eotaxin in 1993, it was suggested that this chemotactic protein
might be important in eosinophil-mediated disease (1). This protein was called
eotaxin since it selectively induced eosinophil migration and did not affect other
granulocytes. In view of the fact that eosinophils might be important in the
pathophysiology of asthma, it was put forward that eotaxin was involved in
eosinophil migration in this disease. Later it became clear that eotaxin, acting via the
CC-chemokine receptor-3 (CCR3), also modulated basophil, Th2, and mast cell
function (2-4). All these cells are implicated in asthma.
In this thesis we aimed to assess the importance of eotaxin in the development of
airway inflammation and airway hyperresponsiveness, characteristic features of
asthma. The mechanism behind the development of these two phenomena is not
entirely clear. It was investigated whether eotaxin or CCR3 are involved in airway
inflammation and airway hyperresponsiveness in order to assess the possibilities of
eotaxin or CCR3 as a potential therapeutic target.
In this thesis different methods were used to obtain insight in the relative
significance of eotaxin in airway eosinophilia and airway hyperresponsiveness. This
issue was addressed by administering eotaxin directly into airways of mice or
humans and accordingly examined in both eosinophil migration to the lungs and
airway function. Furthermore, we used existing animal models for airway
inflammation and hyperresponsiveness induced by either antigen treatment or viral
respiratory infections, and reviewed the role of eotaxin in these models. These
experiments focussed mainly on eosinophils. Moreover, the effect of eotaxin on
mast cells, which are important in initiating and augmenting inflammatory reactions
and might be directly involved in inducing airway hyperresponsiveness, was
investigated.
The main finding of this thesis point towards a disengagement of eotaxin and the
development of airway hyperresponsiveness, and it is unlikely that eotaxin alone
induces eosinophil accumulation in the airways. Our findings have been put in
perspective with data recently published in scientific literature. First, the expression
of eotaxin in inflammatory conditions will be discussed. Second, the role of eotaxin
in airway inflammation will be addressed, distinguishing between eotaxin-induced
eosinophil migration and antigen- or virus-induced airway eosinophilia. Third, the
function of CCR3 expression by mast cells is discussed. Fourth, it is considered
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whether eotaxin is involved in airway hyperresponsiveness. Finally the conclusions
will be summarised.
EOTAXIN EXPRESSION
Under basal conditions eotaxin is expressed in the human airways and is measurable
in serum (5, 6). Asthma patients display increased expression of eotaxin mRNA and
protein in their airways (7-9). Furthermore, during this disease CCR3 is increasingly
expressed on eosinophils in the bone marrow (10).
BALB/c mice used in our experiments express eotaxin under non-inflamed
conditions. Allergen sensitisation and challenge resulted in increased levels of
eotaxin in BAL fluid and lungs (chapter 2). Pro-inflammatory cytokines such as
tumour necrosis factor-α (TNF-α), interleukin (IL)-1β or IL-4 might be responsible
for activation of epithelial and endothelial cells to produce increased amounts of
eotaxin (11). In vivo, these cell types are the main producers of eotaxin during
inflammation (12). Antigen-induced up-regulation of eotaxin expression is
dependent on antigen specific T-cells, since anti-CD3 treatment completely
abolished increased eotaxin production (13). Further, adoptive transfer of Th2 cells
into mice induced antigen-dependent eotaxin expression and airway eosinophilia. In
a mouse model for allergic asthma blockade of Th2 formation also abrogated airway
eosinophilia (14). This suggests that in the airways, eotaxin expression and airway
eosinophilia are Th2 cell-dependent, presumably via the production of Th2-types
cytokines, such as IL-4 and IL-5.
As detected in other studies, this increase in eotaxin expression coincides with
increasing numbers of eosinophils in the airways (9, 15). This was clearly
demonstrated in the experiments done with PI3 infected guinea pigs (chapter 4).
Two days after infection of guinea pigs with PI3 virus, eosinophil numbers in the
broncho-alveolar lavage (BAL) fluid started to increase and was significantly
elevated compared to control treated animals at day three and four after infection.
Interestingly, rising eotaxin concentrations proceeded the influx of eosinophils into
the airways. Two days after infection eotaxin concentrations were increased
compared to non-infected guinea pigs and these levels remained high for at least
four days after infection. This demonstrates that eotaxin levels rise prior to
eosinophil trafficking to the airways, indicating that eotaxin is involved in the
process of trans-migration of these cells. It was shown that respiratory viruses could
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directly induce eotaxin expression from epithelial cells (16, 17). Whether the
increased levels of eotaxin measured in virus infected guinea pigs is directly induced
by respiratory viruses or is indirectly caused by immune reactions to the virus is
unclear.
Thus, increased expression of eotaxin in response to viral infections or antigen
coincides with eosinophil migration to the airways indicating that eotaxin might be
implicated in antigen- and virus-provoked eosinophil migration. However, the fact
that eosinophils start to migrate just after eotaxin levels start to increase does not
necessarily mean that these two events are associated, but these two phenomena can
coincidentally occur at the same time.
AIRWAY INFLAMMATION
Eotaxin-induced eosinophil migration
In order to induce eosinophil migration to the airways, eotaxin concentrations in the
airways were experimentally increased in both mice (chapter 2) and humans
(chapter 6).
Eotaxin instillation into the airways of mice did not induce increased numbers of
eosinophils in the BAL fluid (chapter 2). This indicates that eotaxin alone is not able
to induce eosinophil migration to the airways of mice. An explanation for this might
be that mice do not have many eosinophils in the circulation or tissue. Other
investigators showed that eotaxin induced eosinophil migration (1, 18, 19).
However, in these experiments, guinea pigs, antigen sensitised mice and IL-5
transgenic mice were used. Compared to naïve mice, guinea pigs have a greater pool
of mature eosinophils in their circulation and lung tissue, which are available to
respond to eotaxin. The same is true for antigen sensitised animals and mice that
over-express IL-5 resulting in blood eosinophilia (20). IL-5 primes eosinophils,
which makes them more responsive to eotaxin (21). However, in chapter 2,
intravenous injection of IL-5 did not increase the number of eosinophils or enhanced
responsiveness of these cells to eotaxin. Apparently, high concentrations of IL-5 are
necessary to induce eosinophilia, in vivo.
In chapter 6 it is clearly demonstrated that the number of eosinophils and their
responsiveness might be an important factor that accounts for eotaxin-induced
eosinophil migration. In human atopic asthmatic volunteers eotaxin inhalation
resulted in an increase in eosinophils numbers in the sputum. Quite the opposite,
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inhalation of the same amount of eotaxin in non-atopic non-asthmatics did not result
in increased sputum eosinophils, which is comparable with studies of naïve mice.
Evidently, asthmatic patients showed an enhanced reaction in response to eotaxin
compared to healthy volunteers. Increased numbers of eosinophils in atopic,
asthmatic patients and increased responsiveness of eosinophils might explain this
difference in reaction. Moreover, CCR3 expression on eosinophils or the
responsiveness might be enhanced in asthmatic individuals ((22), Stirling AJRCCM
2001, in press). Various cytokines mediate the increase in number and
responsiveness of eosinophils, for example IL-5. Pro-inflammatory cytokines might
create a suitable environment for eotaxin-induced eosinophil migration. As shown
before, instillation of eotaxin into the nose of patients with allergic rhinitis induced a
significant increase of eosinophils in nasal lavages, subsequently leading to
increased levels of nasal NO and increased rhinitic symptoms (23). This study was
performed in patients with rhinitis, under inflammatory circumstances, but not in
healthy volunteers. Once more, pro-inflammatory environment might augment
eotaxin-induced eosinophil migration.
In order to induce airway eosinophilia, eosinophils should be released from the bone
marrow into the circulation. In virus-infected guinea pigs a clear blood eosinophilia
was demonstrated at day one after infection (chapter 4). Two days after infection the
number of blood eosinophils reached normal levels. This might indicate that these
inflammatory cells migrated from the circulation to the airways. Eotaxin can
stimulate the release of eosinophils form the bone marrow (24). The involvement of
eotaxin in the initiation of blood eosinophilia in our virus model is unlikely, since
eotaxin concentrations started to increase at day 2 of infection. Alternatively, IL-5
could be responsible for the induction of blood eosinophilia (21).
A disadvantage of our studies is that we counted the number of eosinophils in the
BAL fluid and circulation but not in the lung interstitium. Possibly, eosinophils
passed the endothelium but were not triggered to also pass the epithelium. However,
other studies showed that eotaxin is able to initiate eosinophil migration from the
bone marrow all the way to the airway lumen (25-27).
Collectively, eosinophils respond to increasing eotaxin concentrations in vivo,
probably only when the eosinophils are in the right pro-inflammatory environment,
as is the case with atopic asthmatic individuals. This environment might enhance the
number of eosinophils and their responsiveness to eotaxin.
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Antigen- and virus-induced airway inflammation
In order to investigate whether eotaxin takes part in antigen-induced airway
eosinophilia a mouse model for allergic asthma was used. In this model, allergen
challenge of sensitised mice resulted in airway eosinophilia (28). In chapter 3, it is
described that anti-eotaxin antibodies do not influence the number of eosinophils in
the BAL fluid. This indicates that: either treatment with anti-eotaxin antibodies did
not completely block eotaxin, or eotaxin is not involved in eosinophil migration.
However, in another study it was shown that the same amount of antibodies in a
similar mouse model reduced the degree of airway inflammation (29). An
explanation for the contradictory results could be differences in mouse stains used:
BALB/c versus C57/bl6. It is known that different strains of mice react differently to
allergen inhalation (30, 31).
From recent publications it is evident that eotaxin is involved in early stages of
eosinophil migration, as opposed to late. In an ovalbumin model for allergic asthma,
antibodies directed against eotaxin resulted in decreased eosinophil migration only
at day four of repetitive allergen challenge, while at day seven the number of
eosinophils was elevated in equal numbers compared to mice not treated with
antibodies (32). In a cutanous model for late phase reaction, eotaxin expression was
correlated with early rather than late stages of eosinophil recruitment (33).
Furthermore, four hours after allergen provocation in humans the number of
eosinophils correlated with eotaxin expression, while 24 hours later eotaxin
expression declined without decreased levels of eosinophil in the airways (34).
These observations suggest that eotaxin could be involved the in early phase of
eosinophil recruitment while other chemokines might initiate later stages of
eosinophil trafficking. We only investigated the number of eosinophils in the lungs
at the time of established airway eosinophilia. It would be interesting to perform a
time course study in ovalbumin treated mice injected with anti-eotaxin antibodies to
see a difference in kinetics of eosinophil accumulation in the lungs for the course of
eight days of challenge.
Although, eotaxin is able to induce eosinophil trafficking to the lungs, airway
eosinophilia can exists without the presence of eotaxin. A decrease in antigen-
induced airway eosinophilia can co-exist with unaltered eotaxin levels in the airway
(35). Subsequently, airway eosinophilia can exist normally without eotaxin.
Comparable to our results, the previous mentioned studies question the importance
of eotaxin in initiating airway eosinophilia. These data indicate the existence of two
distinct ways for eosinophil accumulation in the airways: one way is eotaxin
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dependent, the other eotaxin independent. Which way of eosinophil migration takes
place depends on the model of eosinophil migration or which animal species or
strains are used.
In addition, eotaxin knockout mice develop equal airway eosinophilia compared to
normal littermates after allergen treatment (36). However, another study showed a
reduced migration of eosinophils to the airways in response to antigen. This was
prominent early after allergen treatment, while at a later time point the number of
eosinophils was increased equally in knockout mice and normal littermates (37).
Investigations on the role of eotaxin in allergen induced eosinophil migration is
complicated by the fact that other chemokines (RANTES, eotaxin-2 and -3,
monocyte chemotactic protein (MCP)-3, -4, -5, and macrophage inflammatory
protein (MIP)-1α) are also active on eosinophils and paralleled with the increase of
eosinophil migration (22). Increased concentrations of all of these chemokines can
lead to eosinophil migration. As a consequence, absence of eotaxin by treatment
with anti-eotaxin antibodies or knockout mice could be compensated by other
chemokines. Eotaxin, -2 and -3 bind selectively to CCR3 and therefore act on
eosinophils, basophils, mast cells, and Th2 cells. Besides binding to CCR3,
RANTES, MIP-1α and MCP-4 bind to CCR1, which is expressed by eosinophils as
well. All these chemokines may contribute to infiltration of eosinophils in the
airways either via activation of CCR1 or CCR3.
Nonetheless, 95% of the eosinophilic response towards these chemokines were
regulated via CCR3, stressing the importance of this chemokine receptor (38).
Therefore, a CCR3 receptor antagonist was used in a guinea pig model for viral
respiratory infections to investigate the role of CCR3 receptor agonists on
eosinophil migration (chapter 4). Surprisingly, CCR3 receptor antagonist treatment
did not result in reduced eosinophil migration to the airways of virus infected guinea
pigs. Once again, CCR3 is not the only chemokine receptor expressed by
eosinophils. In absence of CCR3-mediated response, other chemokines and their
receptor might have taken over. Eosinophil migration is a complex process regulated
by many chemokines, cytokines and their receptor. Thus, blockade of only one
chemokine or chemokine receptor, in this case eotaxin or CCR3, might not be
enough to prevent trafficking of eosinophils in response to an allergic reaction or
infection with a respiratory virus. In a previous study it was shown that antibodies to
IL-5 were not able to decrease airway eosinophilia in response to PI3 virus (39).
Future studies in humans have to ascertain whether impeding the eotaxin response
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with anti-eotaxin antibodies or CCR3 antagonists leads to decreased airway
eosinophilia after allergen provocation or a viral infection.
Other molecules involved in eosinophil recruitment
Besides eotaxin and other chemokines, other molecules have been implicated in
eosinophil recruitment, such as IL-5, very late antigen (VLA)-4, platelet activating
factor, and leukotiene (LT) B4.
Since IL-5 is essential for the maturation of eosinophils, IL-5 was pinpointed as a
suitable therapeutic target to reduce the number of eosinophils in allergic asthma.
Evidence that IL-5 is implicated in asthma is abundant. IL-5 inhalation by asthmatic
patients causes increased levels of eosinophils in sputum and increased airway
responsiveness (40). IL-5 knockout mice failed to develop airway eosinophilia and
airway hyperresponsiveness in response to antigen treatment (41). In a mouse model
for allergic asthma antibodies to IL-5 reduced the number of eosinophils (39). In a
large clinical trial, antibodies to IL-5 reduced the allergen-induced sputum
eosinophilia. Surprisingly, this reduction in cells did not influence the late phase
reaction in response to antigen, questioning the role of IL-5 as a therapeutic target
for asthma (42). In our studies, anti-eotaxin antibodies and CCR3 antagonists were
not effective in decreasing eosinophil recruitment to the airways, questioning the
role of eotaxin as a new therapeutic target. However, combination with other
chemokine receptors or mediators involved in airway inflammation might offer a
better solution in diminishing airway eosinophilia.
MAST CELLS
Mast cells express CCR3 on their surface (3). We tried to investigate the functional
properties of this receptor. Bone marrow-derived mast cells are frequently used to
investigate mechanisms of mast cells degranulation in vitro. Culturing murine bone
marrow cells in IL-3 conditioned medium leads to the formation of a homogenous
mast cell population (43). We demonstrated by flow cytometry that a proportion of
these cells express CCR3 on their surface (chapter 5). Stimulation of these cells with
increasing doses of eotaxin did not result in mast cell granule exocytosis, both in
vivo and in vitro. Furthermore, no leukotiene C4 was formed. These results suggest
that eotaxin stimulation of mast cells does not lead to mast cell activation. In
contrast, eotaxin is able to activate eosinophils and basophils leading to mediator
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release (44, 45). Apparently, the intra-cellular signal transduction pathway is
differently regulated in these cells.
CCR3 on mast cells might be implicated in cell migration. In vitro studies
determined that mast cells migrate to high concentrations of CCR3 ligands (3, 46,
47). Surprisingly, injection eotaxin does not lead to migration of mast cells to the
site of injection in vivo (39). Another function of CCR3 is the development of
embryonic mast cells to mature cells (48).
AIRWAY HYPERRESPONSIVENESS
Airway hyperreactivity is defined as increased reactivity of airway smooth muscle
in response to non-specific stimuli and is a characteristic feature of the allergic
airways. The cause of this phenomenon is unclear. In this thesis it was investigated
whether eotaxin is either directly or indirectly involved in airway
hyperresponsiveness.
Eosinophils and airway hyperresponsiveness
During the late phase reaction airway eosinophilia and airway hyperresponsiveness
often occur together (49). Whether there is a causal relationship between the degree
of airway hyperresponsiveness and the number of eosinophils in the airways
remains topic of debate.
Evidence that these two characteristics correlate is numerous. Many clinical studies
have found a relationship between the number of eosinophils or eosinophil-specific
mediators and disease severity. For example, the numbers of eosinophils in the
airways are inversely correlated with PC20 (50, 51). Moreover, eosinophils and their
cationic products were shown to directly induce airway hyperresponsiveness (52).
Further evidence that eosinophils influence airway responsiveness comes from
results obtained with glucocorticoids. Treatment with anti-inflammatory drugs
reduces the number of eosinophils, which goes together with a reduction of airway
symptoms.
On the other hand, support that these two features coincidentally happen at the same
time and do not influence each other is accumulating. Airway eosinophilia can
exists without airway hyperresponsiveness, as seen in eosinophilic bronchitis,
suggesting that the mere presence of eosinophils in the airways is not enough for
inducing airway hyperresponsiveness (39, 53). The other way around, airway
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hyperresponsiveness can take place without the presence of eosinophils in the
airways (42). This implies that airway inflammation and hyperresponsiveness are
independently regulated but closely interrelated (49). This was also shown in our
laboratory. Although IL-5 antibodies abrogated airway eosinophilia in mice treated
with ovalbumin, airway hyperreactivity could still be demonstrated (53). On the
other hand, antibodies to IL-5 abolished airway hyperreactivity without affecting the
number of eosinophils in a guinea pig model for allergic asthma (39).
In conclusion, airway hyperresponsiveness can take place without the presence of
eosinophils. Nevertheless, airway eosinophils can influence the degree of airway
responsiveness. Therefore, eotaxin might influence airway responsiveness by
inducing accumulation of eosinophils to the airways.
Eotaxin and airway hyperresponsiveness
Several clinical studies support the hypothesis that eotaxin and airway
hyperresponsiveness are associated. In a cross-sectional study, serum eotaxin levels
were elevated in acute asthmatics compared to stable asthmatic controls (6).
Additionally, plasma eotaxin levels were inversely correlated with lung function
(54). The number of eotaxin positive cells is related to the degree of airway
hyperresponsiveness (8).
In chapter 2, eotaxin did not directly influence airway responsiveness. This might be
explained by the fact that eotaxin did not induce airway eosinophilia. On the other
hand, eotaxin also acts on other cells such as basophils, Th2 cells and mast cells.
These cells are not abundantly present in the airways of naïve mice. Therefore,
eotaxin might not influence reactivity of naive murine airways. Although eotaxin
inhalation in human mild asthmatic individuals caused an increase in sputum
eosinophils no changes in airway function (FEV1 and PC20 to methacholine) were
detectable (chapter 6). To keep in mind, these changes in sputum eosinophils were
very small and therefore might not have influenced airway responsiveness.
Injection of eotaxin in saline challenged mice did not influence airway
responsiveness. Treatment with eotaxin prolonged the period of airway
hyperresponsiveness in ovalbumin challenged and sensitised mice (chapter 3). This
might indicate that eotaxin is not involved in the development of airway
hyperresponsiveness, but it can influence existing airway responsiveness.
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Some remaining questions
The last eight years a lot of research is done to clarify the role of eotaxin in airway
pathology. Despite this intensive research a lot of questions remain to be elucidated.
Why is eotaxin over-expressed during allergen challenge and how is it regulated?
During an allergic reaction eotaxin is increasingly expressed. This might illustrates
the importance of eotaxin in airway pathology indicating that this expression is
functional. On the other hand, eotaxin could be expressed because it is induced by
pro-inflammatory cytokines and has similar signal transduction pathways compared
to other inflammatory cytokines, involving NFκB for example.
Why is there so much redundancy and promiscuity in the chemokine system?
This is an intriguing question. Multiple receptors are present on one type of cell;
there are multiple receptors for one ligand and one ligand for multiple receptor; and
multiple ligands and receptors evoke the same cellular function. The purpose of this
redundancy is not clear; however, in this way a tightly regulated network is formed.
Small changes in expression can have big consequences, or big changes might have
small consequences. Furthermore, one process can be regulated by various
chemokines/receptors at different stages.
What are the roles of different forms of eotaxin?
This question relates to the previous question. At first eotaxin was believed to be
special since it only bound to CCR3. Nowadays, eotaxin-2 and -3 are discovered
which are also selective for CCR3. The specific roles of these restricted CCR3
receptor agonists remains to be elucidates. It might be that these three chemokines
participate in different stages of airway inflammation (63).
Why is eotaxin expressed in organs that do not home eosinophils?
Eotaxin is expressed under basal, non-inflamed circumstances, and therefore is
involved in basal tissue homing of eosinophils (37). However, organs that do not
home eosinophils under basal condition also express eotaxin. This might indicate an
unknown function for eotaxin.
Will CCR3 antagonists block eosinophil accumulation and thereby prevent lung
pathology?
Of course this is an important question with regard to treatment of asthma. From this
thesis and other data it seems unlikely that one antagonist is able to block eosinophil
migration. Blockade of multiple chemokine receptor might be a better alternative to
prevent airway eosinophilia. Furthermore, whether reduced airway eosinophilia will
decrease airway symptoms remains to be elucidated.
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In order for eosinophils to influence airway responsiveness, these cells need to be
activated. Eotaxin can activate eosinophils to release toxic products and
inflammatory mediators (55-57). We could not demonstrate eosinophil activation by
eotaxin in vivo (chapter 2, and 3). Addition of eotaxin to airways of ovalbumin
challenged mice did not result in increased release of eosinophil peroxidase (EPO).
Surprisingly, no increased levels of EPO were detectable in mice sensitised and
challenged with ovalbumin compared to mice challenged with saline (chapter 3 and
(28)). Challenge of mice for 8 consecutive days might have exhausted eosinophils of
EPO by the time of measurement (chapter 3). Therefore, the prolonged effect of
airway hyperresponsiveness might be due to effect of eotaxin on other cells.
Similar to our data, other investigators showed, that eotaxin alone is not able to
induce airway hyperresponsiveness in guinea pigs. Administration of eotaxin into
the airways resulted in accumulation of eosinophils to the airways without airway
hyperresponsiveness (25). Subsequently, inhalation of platelet activating factor was
necessary to induce eosinophil activation resulting in airway hyperresponsiveness
(25). In another study, eotaxin instillation to IL-5 transgenic mice induced airway
hyperresponsiveness (58). Interestingly, LTC4 receptor antagonists blocked the
eotaxin-induced airway hyperresponsiveness. Both these studies suggest that eotaxin
can only induce hyperreactivity in combination with other mediators, e.g. platelet
activating factor and IL-5.
Thus, the mere presence of eosinophils in the airways is not enough to induce
airway hyperreactivity. Eosinophils need to be activated and release their toxic
proteins in order to induce airway hyperreactivity. Mould and colleagues
demonstrated that gene transfer of IL-5 and eotaxin induced airway eosinophilia but
not eosinophil degranulation and airway hyperresponsiveness. In association with
IL-5 and eotaxin expression, antigen inhalation was required for eosinophil
degranulation and airway hyperresponsiveness to occur (26). This suggests that
other factors in association with IL-5 and eotaxin trigger eosinophil degranulation
and subsequently leading to airway hyperresponsiveness. Reviewing experiments on
airway hyperreactivity, one has to keep in mind that there are differences between
mouse and human eosinophils. Malm-Erjefält and colleagues demonstrated that
murine eosinophils do not degranulate in response to allergen while human
eosinophils do (59). Furthermore, there are differences in content of eosinophil
granula as well as surface molecules (60). In comparison, no eosinophil activation
could be demonstrated after allergen challenge, as measured by EPO levels in
chapter three.
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Treatment of mice with antibodies to eotaxin and guinea pigs with CCR3 receptor
antagonists did not change antigen- or virus-induced airway hyperresponsiveness,
respectively. Again, this indicates that eotaxin is not directly involved in airway
hyperresponsiveness. However, these results might be explained by the fact that this
treatment did not alter eosinophil numbers in the BAL fluid. In another study
eotaxin antibodies were able to reduce the ovalbumin-induced airway
hyperresponsiveness only partly (29).
Despite the role of eosinophils, activation of mast cells can also lead to airway
hyperresponsiveness. In the early phase reaction, mast cells induce airway
hyperresponsiveness by IgE-dependent activation, leading to the release of broncho-
constrictive mediators, such as histamine and LTC4. Through the production of
cytokines and chemokines mast cells contribute to the late phase reaction (61). From
chapter 5 it is clear that eotaxin does not activate bone marrow-derived mast cells.
In spite of this, eotaxin might induce and augment the inflammatory reaction by
attracting mast cells to the site of inflammation in this way contributing to airway
hyperresponsiveness. In the late phase reaction increased numbers of mast cells are
present in the lungs (62). In the airways other inflammatory cytokines could induce
mast cells activation and therefore airway hyperresponsiveness.
Taken together, it is unlikely that eotaxin is able to induce airway hyperreactivity
single-handedly. In humans, eotaxin might enhance airway hyperresponsiveness by
inducing airway eosinophilia, while in mice eotaxin is involved in maintaining this
condition. Although eotaxin did not lead to mast cell degranulation, eotaxin might
be involved in migration of these cells to the lungs and thereby augmenting airway
hyperresponsiveness.
CONCLUSION
This thesis started out with addressing three questions (see page 21 and 22). The
results described in this thesis lead to the following answers:
1. Does eotaxin instillation in the airways cause airway eosinophilia and airway
hyperresponsiveness? From chapter 2, we conclude that eotaxin does not induce
trafficking of eosinophils, and eotaxin is not involved in airway
hyperresponsiveness. In contrast, in human asthmatic volunteers eotaxin induced a
small increase in sputum eosinophils. This indicates that eotaxin only induces
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eosinophil migration under inflammatory circumstances. However, eotaxin is not
involved in airway hyperresponsiveness.
2. Is antigen- or virus-induces airway inflammation and airway
hyperresponsiveness regulated by eotaxin? Although eotaxin expression increases
during a viral respiratory infection or after allergen challenge, blockade of eotaxin
or its receptor did not result in changes in airway eosinophilia and airway
hyperresponsiveness. These studies demonstrate that eotaxin is not important in
virus- or antigen-induced airway inflammation and hyperresponsiveness.
3. Can eotaxin activate mast cells and thereby induce airway inflammation and
hyperresponsiveness? Although mast cells express CCR3 on their surface,
stimulation of this receptor with eotaxin does not result in mast cells activation.
Therefore, it is unlikely that eotaxin induces airway pathology by activating mast
cells
Taken together, these results question the importance of eotaxin and its receptor as a
therapeutic agent. Although eotaxin protein is increased in asthmatic patients,
eotaxin is not involved in airway eosinophilia and hyperresponsiveness. There are a
lot of mediators, which are able to induce eosinophil migration. In my opinion,
antagonising multiple chemokine receptors might be more effective in blocking
eosinophil migration, than blocking only CCR3.
Eotaxin does not induce airway hyperresponsiveness. In addition, it is unclear
whether reducing airway eosinophilia will lower the degree of airway
hyperresponsiveness. Therefore, eotaxin or CCR3 receptor antagonists might not be
suitable targets for future asthma therapy.
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Een karakteristieke eigenschap van astma is ontsteking van de luchtwegen. Deze
ontsteking wordt gekenmerkt door een toename van ontstekingscellen in het
longweefsel. De overgrote meerderheid van deze cellen bestaat uit zogenaamde
eosinofiele granulocyten. Deze cellen ontwikkelen zich in het beenmerg. Onder niet-
allergische omstandigheden komen deze cellen via het bloed in de darmen terecht
waar zij het lichaam beschermen tegen parasieten door het uitscheiden van toxische
stoffen. In het geval van astma komen er meer eosinofiele granulocyten vrij uit het
beenmerg, en migreren deze cellen naar de longen. Eenmaal in de luchtwegen
kunnen deze cellen toxische stoffen uitscheiden en schade berokkenen aan het
longweefsel.
Een ander kenmerk van astma is luchtwegovergevoeligheid, ook wel luchtweg-
hyperreactiviteit genoemd. Luchtwegovergevoeligheid is het overmatig
samentrekken van glad spierweefsel in de luchtwegen als reactie op specifieke
prikkels, zoals allergenen, of aspecifieke prikkels, zoals koude lucht. Hoe dit
fenomeen tot stand komt is onbekend. In de literatuur wordt verondersteld dat de
grote hoeveelheid eosinofiele granulocyten in de longen de
luchtweghyperreactiviteit kan beinvloeden. De toxische stoffen uit deze cellen
kunnen direct luchtweghyperreactiviteit veroorzaken door de gladde spieren in de
trachea samen te trekken. Maar hyperreactiviteit kan ook ontstaan doordat
eosinofiele granulocyten weefselschade kunnen veroorzaken. De rol van de
eosinofiele granulocyten bij het ontstaan van luchtweghyperreactiviteit is echter niet
onomstotelijk bewezen. Bijvoorbeeld, zonder eosinofiele granulocyten kan er
luchtwegovergevoeligheid optreden en aanwezigheid van eosinofiele granulocyten
leidt niet altijd tot luchtweghyperreactiviteit.
Chemokines zijn mediatoren die betrokken zijn bij migratie van cellen. Deze
eiwitten leiden de cellen naar de plaats van bestemming. Cellen die hiervoor
gevoelig zijn migreren naar hoge concentraties van een bepaald chemokine. Bij
astmapatiënten moet er ook een signaal vanuit de longen komen die zorgen dat
eosinofiele granulocyten naar de luchtwegen migreren. Eotaxine is een chemokine
die in staat is om eosinofiele granulocyten aan te trekken. In de luchtwegen van
astmatici wordt er veel van dit eiwit geproduceerd. Daarom wordt verondersteld dat
eotaxine een belangrijke rol kan spelen bij astma.
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De experimenten beschreven in dit proefschrift hebben tot doel de rol van eotaxine
bij het ontstaan van ontsteking in de longen en luchtwegovergevoeligheid te
bepalen. Onze hypothese is dat onder allergische omstandigheden eotaxine in de
luchtwegen wordt geproduceerd en eosinofiele granulocyten naar de longen trekt en
activeert. Aangezien de aanwezigheid van deze eosinofiele granulocyten kan leiden
tot luchtweg-overgevoeligheid, kan eotaxine betrokken zijn bij het ontstaan van
luchtweg-hyperreactiviteit. Als eotaxine inderdaad betrokken is bij het ontstaan van
luchtweg-ontsteking en -overgevoeligheid dan zou eotaxine wel eens een belangrijk
aangrijpings-punt kunnen zijn voor een nieuw medicijn tegen allergie en astma.
Op verschillende manieren is onderzocht of eotaxine betrokken is bij luchtweg-
ontsteking en -overgevoeligheid. Ten eerste is onderzocht of verhoogde eotaxine
concentraties in de luchtwegen resulteerde in een verhoging van het aantal
eosinofiele granulocyten in de luchtwegen en of dit gevolgen heeft voor de
luchtwegfunctie van zowel proefdieren als mensen. Vervolgens is gebruik gemaakt
van bestaande diermodellen voor allergische astma en virale luchtweginfecties om te
onderzoeken of eotaxine van belang was bij de migratie van eosinofiele
granulocyten in deze modellen. In hoofdstuk 5 is de functionele rol van de eotaxine
receptor bij de mestcel onderzocht.
Verhoging van eotaxine concentraties in de luchtwegen
Om te onderzoeken of eotaxine de trachea direct kan samen trekken werden trachea
segmenten van muizen in een orgaanbad geanalyseerd. Sommige stoffen zijn in staat
om het gladde spierweefsel in de trachea te doen samen trekken. Uit de resultaten
beschreven in hoofdstuk 2 blijkt dat eotaxine de trachea niet direct kan samen
trekken en de trachea niet gevoeliger maakt voor andere contractiele agentia. Met
andere woorden, eotaxine induceert niet direct luchtweghyperreactiviteit.
Vervolgens werden muizen behandeld met eotaxine. Deze mediator werd direct in
de trachea geïnjecteerd. Uit deze experimenten bleek dat dit geen gevolgen had voor
de longfunctie van de muizen. Een manier om de mate van luchtwegontsteking te
bepalen is door de longen te spoelen en in de longspoelvloeistof, broncho-alveolaire
lavage (BAL)-vloeistof, het aantal ontstekingscellen te bepalen. In de BAL-vloeistof
van muizen behandeld met eotaxine werden geen eosinofiele granulocyten
aangetroffen. In dit hoofdstuk wordt geconcludeerd dat eotaxine geen effect heeft op
de luchtwegen wat betreft de functie en celinflux in deze muizen.
Tevens is er een klinische studie gedaan om te onderzoeken of inhalatie van
eotaxine door astmatische en gezonde vrijwilligers invloed heeft op de mate van
ontsteking en overgevoeligheid van de luchtwegen. Allergische astmapatiënten en
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gezonde vrijwilligers werden gevraagd om eotaxine of placebo te inhaleren. Vijf, 24
en 48 uur na de inhalatie werd de mate van ontsteking van de luchtwegen bepaald en
vergeleken met de basaalwaarden. De mate van ontsteking is bepaald door het
percentage ontstekingscellen in sputum van patiënten te bepalen. Onderzoek heeft
uitgewezen dat dit een betrouwbare manier is om de mate van luchtwegontsteking te
bepalen. Inhalatie van eotaxine leidde in astmapatiënten tot een verhoging van het
percentage eosinofiele granulocyten in het sputum. Dit was niet het geval bij
gezonde vrijwilligers. Verhoging van de eotaxine concentratie in de luchtwegen
zorgt dus voor een verhoogde mate van ontsteking van de luchtwegen bij
astmapatiënten. Het verschil tussen astmatische en niet astmatische patiënten zou
verklaard kunnen worden door de hoeveelheid beschikbare eosinofiele granulocyten
en de mate van gevoeligheid van deze cellen. Patiënten met astma hebben een groter
aantal eosinofiele granulocyten die onder invloed van ontstekingsmediatoren
gevoeliger zijn en daardoor dus eerder reageren op eotaxine. Echter, de verhoging
van het aantal eosinofiele granulocyten in het sputum van astmapatiënten was maar
klein en had geen gevolgen voor de luchtwegfunctie.
Allergeen- en virus-geïnduceede ontsteking en luchtwegovergevoeligheid
Er werd ook gebruik gemaakt van diermodellen om de rol van eotaxine bij het
ontstaan van luchtwegovergevoeligheid en -ontsteking te bepalen. In een muismodel
voor allergische astma worden muizen overgevoelig gemaakt voor ovalbumine (een
kippeneieiwit) door muizen te injecteren met dit eiwit. Dit gebeurt in de
sensibilisatiefase. Deze fase wordt gevolgd door een provocatie, de challengefase. In
deze periode worden muizen blootgesteld aan een nevel van ovalbumine. Deze
behandeling leidt tot een verhoging van het aantal eosinofiele granulocyten in de
BAL-vloeistof en een verhoging van de luchtweggevoeligheid. Uit de experimenten
van hoofdstuk 3 blijkt tevens dat de hoeveelheid eotaxine in de luchtwegen is
verhoogd in de muizen die met ovalbumine behandeld waren. Behandeling van deze
muizen met antilichamen tegen eotaxine had echter geen invloed op de door
ovalbumine geïnduceerde ontsteking en luchtweghyperreactiviteit. Dit duidt erop
dat eotaxine niet belangrijk is voor het ontstaan van deze symptomen.
Virale luchtweginfecties veroorzaken ontsteking en luchtwegovergevoeligheid. Bij
astmapatiënten kan een infectie zorgen voor verslechtering van de symptomen van
astma. Om het mechanisme van het ontstaan van luchtweghyperreactiviteit tijdens
een virale luchtweginfectie te onderzoeken werd er gebruik gemaakt van een
caviamodel, waarin deze dieren geïnfecteerd worden met parainfluenza virus. Deze
behandeling leidt tot luchtwegovergevoeligheid en -ontsteking. In hoofdstuk 4 is
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onderzocht of eotaxine een rol speelt in dit caviamodel. De migratie van eosinofiele
granulocyten na de infectie werd in kaart gebracht. Eén dag na de ontsteking is het
aantal ontstekingscellen in het bloed verhoogd. Twee dagen na infectie verdwijnen
deze cellen uit het bloed en komen de ontstekingscellen in de longen terecht. Het
aantal eosinofiele granulocyten in de longen stijgt tot en met dag vier van de
infectie. Het lijkt er dus op dat eerst de cellen uit het beenmerg naar het bloed
migreren en vervolgens naar de luchtwegen. Vlak voor de stijging van het aantal
eosinofiele granulocyten in de luchtwegen stijgt ook de hoeveelheid eotaxine in de
BAL vloeistof. Dit zou erop kunnen duiden dat eotaxine het signaal is voor de
eosinofiele granulocyten om te migreren naar de luchtwegen. Echter, blokkade van
de eotaxine receptor heeft geen gevolgen voor de eosinofiele granulocyt migratie.
Deze experimenten laten zien dat de eotaxine productie door ovalbumine
behandeling of een virale luchtweginfectie wordt verhoogd, maar dat eotaxine niet
als enige betrokken is bij het ontstaan van luchtwegontsteking en
luchtwegovergevoeligheid. Er zijn meerdere ontstekingsmediatoren die in staat zijn
om selectief eosinofiele granulocyten aan te trekken die in deze modellen ook van
belang kunnen zijn. Waarschijnlijk moeten er meerdere mediatoren geblokkeerd
worden om te voorkomen dat eosinofiele granulocyten naar de luchtwegen
migreren.
Mestcellen
Mestcellen spelen een belangrijke rol bij het ontstaan en onderhouden van een
ontsteking. Recent onderzoek heeft uitgewezen dat de receptor voor eotaxine op
mestcellen aanwezig is. Om het mechanisme van activatie van de mestcel te
onderzoeken wordt er gebruik gemaakt van zogenaamde bone marrow-derived mast
cells (BMMCs). Dit zijn beenmergcellen van muizen die onder invloed van de
kweekomstandigheden uitgroeien tot mestcellen. Het doel van de experimenten
beschreven in hoofdstuk 5 was om aan te tonen dat BMMCs de eotaxine receptor
bezitten en te onderzoeken of eotaxine via deze receptor mestcellen kan activeren.
In dit hoofdstuk laten wij zien dat een deel van deze cellen de receptor voor eotaxine
bezit. Incubatie van deze cellen met eotaxine leidt echter niet tot activatie van
BMMCs. Toenemende concentraties van eotaxine resulteerden niet in het uitstoten
van mediatoren door de mestcellen. In muizen leidt intraveneuze injectie met
eotaxine ook niet tot een verhoging van de concentratie mediatoren specifiek voor
de mest cel in het bloed. Eotaxine draagt dus niet bij aan de ontstekingsreactie door
activatie van mestcellen. Echter, de rol van eotaxine in het ontstekingsproces zou
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kunnen zijn dat eotaxine zorgt voor de migratie van mestcellen naar de plek van
ontsteking.
Conclusie
Uit dit onderzoek blijkt dat eotaxine alleen migratie van eosinofiele granulocyten
veroorzaakt onder allergische omstandigheden, aangezien alleen astmatici reageren
op een verhoogde concentraties van eotaxine in de luchtwegen. Eotaxine alleen is
niet in staat om luchtwegovergevoeligheid te veroorzaken.
Aangezien blokkeren van eotaxine of van de receptor in onze diermodellen niet
zorgt voor een vermindering van de luchtwegsymptomen, lijkt eotaxine geen goede
kandidaat als aangrijpingspunt voor een nieuw medicijn. Nader onderzoek moet
uitwijzen of blokkeren van eotaxine of de receptor in astmapatiënten zal leiden tot
een vermindering van de klachten.
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ABBREVIATIONS
ANOVA Analysis of variance
BAL Broncho-alveolar lavage
BLC B-lymphocyte chemokine
BMMCs Bone marrow-derived mast
cells
BSA Bovine serum albumin
CCR CC-chemokine receptor
cDNA Copy DNA
CKR Chemokine receptor
CO Carbon monoxide
CTACK Cutanous T-cell attracting
chemokine
DTT 1,4-Dithio-DL-threitol
ECP Eosinophilic cationic protein
END Eosinophil-derived
neurotoxin
EPO Eosinophil peroxidase
FCS Fetal calf serum
FEV1 Forced expiratory volume in
1 second
GCP Granulocyte chemotactic
protein
GM-CSF Granulocyte-macrophage
colony stimulating factor
GRO Growth related protein
HBSS Hank’s balanced salt solution
HRP Horseradish peroxidase
HSA Human serum albumin
ICAM Inducible cell adhesion
molecule
Ig Immunoglobulin
IL Interleukin
IP Interferon-gamma inducible
protein
iTAC inducible T cell-alpha
chemoattractant
LARC Liver and activation related
chemokine
LFA Lymphocyte function
associated antigen
LT Leukotriene
MAC Complement receptor-3
MBP Major basic protein
MCP Monocyte chemotactic
protein
MDC Monocyte-derived chemokine
MEC Mammary enriched
chemokine
MiG monocyte-induced by
interferon -γ
MIP Macrophage inflammatory
protein
mRNA Messenger RNA
NAP Neutrophil activating peptide
NO Nitric oxide
PBS Phosphate buffered saline
Penh Enhanced pause
PI Para-influenza
PWM-SCM Pokeweed mitogen
stimulated- spleen cell
conditioned medium
RANTES Regulated upon activation
normal T cell expressed and
secreted
RIA Radio immuno assay
SDF Stromal cell-derived factor
SEM Standard error of the mean
SLC Secondairy lymphoid tissue
chemokine
TARC Thymus and activation
related protein
TECK Thymus expressed
chemokine
TNF Tumor necrosis factor
VCAM Vascular cell adhesion
molecule
VLA Very late antigen
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